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ABSTRACT 
SELECTIVE ANTIBODY REMOVAL FROM BLOOD, PLASMA AND BUFFER USING 
HOLLOW FIBER-BASED SPECIFIC ANTIBODY FILTERS 
Mariah Sydney Hout, Ph.D. 
University of Pittsburgh, 2003 
Therapeutic antibody removal is performed to facilitate ABO-incompatible kidney 
transplants and heart and kidney xenotransplants, and to treat Goodpasture syndrome, 
myasthenia gravis, hemophilia with inhibitors, and thrombocytopenic purpura. Antibody removal 
is achieved non-selectively, via plasma exchange, or semi-selectively, via plasma perfusion 
through immunoadsorption columns containing immobilized protein A. We are developing 
hollow fiber-based specific antibody filters (SAFs) that selectively remove antibodies of a given 
specificity directly from whole blood, without separation of the plasma and cellular blood 
components and with minimal removal of plasma proteins other than the targeted antibodies. The 
working unit of the SAF is a hollow fiber dialysis membrane with antigens, specific for targeted 
antibodies, immobilized on the inner fiber wall. Several thousand SAF fibers are connected in 
parallel to produce a filter similar in construction to a hollow fiber hemodialyzer. A principal 
goal of our research is to identify the primary mechanisms that control antibody transport within 
the SAF, and to use this information to guide the choice of design and operational parameters 
that maximize the SAF-based antibody removal rate. We approached this goal by formulating a 
simple mathematical model of SAF-based antibody removal and performing in vitro antibody 
removal experiments to test key predictions of the model. Our model revealed three antibody 
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transport regimes, defined by the magnitude of the Damköhler number Da (antibody-binding 
rate/antibody diffusion rate): reaction-limited (Da ≤ 0.1), intermediate (0.1 < Da < 10), and 
diffusion-limited (Da ≥ 10). For a given SAF geometry, blood flow rate, and antibody 
diffusivity, the highest antibody removal rate was predicted for diffusion-limited antibody 
transport. We performed in vitro antibody removal experiments in which SAFs containing 
immobilized bovine albumin (BSA) were used to remove anti-BSA antibodies from buffer. The 
measured anti-BSA removal rates were consistent with antibody transport in the intermediate 
regime. We concluded that initial SAF development work should focus on achieving diffusion-
limited antibody transport by maximizing the SAF antibody-binding capacity. If diffusion-
limited antibody transport is achieved, the antibody removal rate can be raised further by 
increasing the number and length of the SAF fibers and by increasing the blood flow rate through 
the SAF. 
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 1.0 INTRODUCTION 
Antibodies are specialized glycoproteins that mediate humoral immunity by binding 
specifically to the antigens that induced their synthesis, either neutralizing the microorganisms 
bearing the antigens or initiating their destruction by phagocytosis, complement-mediated lysis, 
or antibody-dependent cell-mediated cytotoxicity (1). Though normally beneficial, antibodies 
may be harmful if they bind to antigens on self-cells or self-tissues (self-antigens). The healthy 
immune system has self-tolerance mechanisms that delete self-reactive lymphocytes or regulate 
their activity; when these mechanisms fail due to an autoimmune disease, self-antigen-binding 
antibodies may be produced. Additionally, organ transplant recipients may experience damage to 
the transplanted donor organ by antibodies that bind to non-self antigens on cells within the 
donor organ (donor-specific antibodies). Donor-specific antibodies are produced as part of the 
healthy immune system’s response to the non-self antigens within the donor organ, and are not 
indicative of an immune system disorder. 
Therapeutic removal of self-antigen-binding antibodies is performed to treat autoimmune 
diseases like Goodpasture syndrome (2), myasthenia gravis (3), hemophilia with inhibitors (4), 
and idiopathic thrombocytopenic purpura (5), while therapeutic removal of donor-specific 
antibodies is performed to facilitate ABO-incompatible kidney transplants (6) and heart (7) and 
kidney (8) xenotransplants (pig-to-baboon). Antibody removal is usually achieved non-
selectively, via plasma exchange, or semi-selectively, via plasma perfusion through 
immunoadsorption columns containing immobilized protein A or anti-human immunoglobulin 
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 (9-13). Most complications of plasma exchange are related to the replacement fluid; replacement 
with albumin solution may cause deficiency syndromes since beneficial antibodies and clotting 
factors are not replenished, while replacement with donor plasma may trigger hypersensitivity 
reactions or allow infectious disease transmission (9). Patients treated using protein A or anti-
human immunoglobulin immunoadsorption columns benefit from selective IgG or IgM removal 
and require little to no replacement fluid (10-13). However, only a small fraction of the total 
antibody population (often only antibodies of one specificity) need be removed to effect the 
treatments listed above, and antibody removal platforms with even greater selectivity are desired. 
We are developing hollow fiber-based specific antibody filters (SAFs) that selectively 
remove antibodies of a given specificity directly from whole blood, without separation of the 
plasma and cellular blood components and with minimal removal of plasma proteins other than 
the targeted antibodies (14,15). The working unit of the SAF is a hollow fiber dialysis membrane 
with antigens, specific for targeted self-antigen-binding or donor-specific antibodies, 
immobilized on the inner fiber wall (Figure 1-1). Several thousand SAF fibers are connected in 
parallel to produce a filter similar in construction to a hollow fiber hemodialyzer. During SAF-
based antibody removal blood flows through the fiber lumens, and the targeted antibodies bind to 
the immobilized antigens and become trapped within the SAF. Hydrophilic cellulose-based SAF 
fibers are used to minimize non-specific protein adsorption within the SAF, and hence the levels 
of non-targeted antibodies and other plasma proteins are relatively unchanged following SAF-
based antibody removal. 
Several studies, including two conducted by our own group (14,15), have shown that 
SAFs and similar filters can selectively remove antibodies and other substances from blood, 
plasma, and buffer (16-19). However, SAF-based antibody removal must be reasonably fast as 
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 well as selective if the platform is to be clinically valuable. A principal goal of our research is to 
identify the primary mechanisms that control antibody transport within the SAF, and to use this 
information to guide the choice of design and operational parameters that maximize the SAF-
based antibody removal rate. We approached this goal by performing studies with the following 
specific aims: 
1. Show “proof of concept” by using SAF prototypes with immobilized A and B blood 
group antigens to remove anti-A and anti-B antibodies from type A and O whole human 
blood samples. 
2. Develop a mathematical antibody transport model that describes antibody diffusion, 
convection, and reversible binding within the SAF fibers. Use the model to predict the 
magnitude of the SAF-based antibody removal rate, and to identify the removal rate-
controlling antibody transport mechanisms, for clinically relevant SAF geometries, blood 
flow rates, antibody diffusivities, and antibody-binding rates. 
3. Identify an appropriate model antibody/antigen system for use during quantitative in vitro 
antibody removal experiments. Fabricate SAF prototypes with the model antigens 
immobilized on the lumenal surfaces of the hollow fibers. 
4. Perform in vitro antibody removal experiments in which SAF prototypes with 
immobilized model antigens are used to remove model antibodies from aqueous buffer. 
Test key predictions of the mathematical antibody transport model, including the 
dependence of the antibody removal rate on the buffer flow rate and the SAF antibody-
binding capacity. 
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 5. Use the information gained from the combined mathematical and experimental studies to 
suggest design, development, and operational approaches that can be taken to maximize 
the antibody removal rates achieved by SAFs developed for clinical use. 
Targeted Antibody (Ab) Immobilized Antigen (Ag)
Non-Targeted Antibody
or Other Plasma Protein
Membrane Wall
free Ab 
bound Abimmobilized Ag 
Blood Flow
 
Figure 1-1 Schematic depicting antibody removal in the lumen of a 
SAF fiber. The relative dimensions of the fiber lumen and the 
antibodies and antigens are not to scale. 
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 2.0 BACKGROUND 
2.1 Antibody Structure and Function 
Antibodies have distinct structural features that allow them to bind to antigens and to 
initiate the destruction of antigens and antigen-bearing microorganisms (1). Each antibody 
molecule consists of one or more copies of a characteristic Y-shaped unit formed by four 
polypeptide chains, two identical light chains and two identical heavy chains. The stem of the Y 
is comprised of the carboxyl-terminal parts of the two heavy chains, and each arm is comprised 
of the amino-terminal part of a heavy chain and an entire light chain (Figure 2-1). One antigen-
binding site is located near the tip of each arm, and moieties that dictate the antibody’s effector 
functions are located on the stem. Brief digestion of an antibody molecule by papain breaks the 
arms from the stem; the arms are referred to as Fab fragments, since they have antigen-binding 
activity, while the stem is referred to as an Fc fragment, since the stem fragments crystallize 
during cold storage. 
Each light chain and heavy chain has a variable region, in which the amino acid sequence 
varies for antibodies of different antigen-binding specificities, and a constant region, in which 
the amino acid sequence is conserved for all antibodies of a given class and subclass, bearing 
light chains of a given subtype (Figure 2-1) (1). The variable region consists of the first 100-110 
amino acids of the chain (beginning with the amino-terminal residue), and the constant region 
consists of the remaining 110 amino acids (light chains) or 330 or 440 amino acids (heavy 
chains). At the tip of each arm, an antigen-binding site is formed by three hypervariable regions 
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 within the variable region of the light chain and three within the variable region of the heavy 
chain. The hypervariable regions constitute 15-20% of the variable region, and relatively 
invariant framework sequences constitute the rest. 
C C
Light chain
Heavy chain
Antigen-binding sites
Constant 
region
Va
ria
ble
 
reg
ion
Disulphide bonds
N 
 N
N  N
CC
 
Figure 2-1 Basic structure of an antibody molecule. Hatching 
indicates the variable region of each chain. The number of 
interchain disulphide bonds varies with antibody class and 
subclass; intrachain disulphide bonds are not shown. N: amino-
terminal end of the polypeptide chain. C: carboxyl-terminal end 
of the chain. 
Humans have five antibody classes, and each class has its own arsenal of effector 
functions (1). The class of a given antibody molecule is determined by the amino acid sequence 
of its heavy chain constant region; the five classes, IgG, IgM, IgA, IgE, and IgD, have heavy 
chains named , , , , andrespectively. IgG, IgE, and IgD antibodies exist as monomers of 
the Y-shaped unit shown in Figure 2-1, while IgM antibodies exist mostly as pentamers and IgA 
antibodies exist as monomers in blood but as dimers in external secretions. When bound to 
antigens, both IgG and IgM antibodies activate complement by binding to C1 molecules via C1-
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 binding sites on the Fc regions of the antibodies. Stable C1/antibody binding requires that each 
C1 molecule bind to at least two Fc regions, and hence IgM antibodies are more potent 
complement activators than IgG antibodies since one IgM antibody molecule provides five Fc 
regions in close proximity. IgG antibodies also acts as opsonins by binding to Fc receptors on 
phagocytes, and confer fetal and neonatal immunity by crossing the placenta. Dimeric IgA is the 
predominant antibody class in external secretions like breast milk, saliva, tears, and mucus, and 
in these secretions IgA antibodies crosslink large antigens like viruses and bacteria. Crosslinking 
prevents viruses and bacteria from attaching to mucosal cells, and the large antibody/antigen 
complexes formed become trapped in mucus and are eliminated. IgE antibodies mediate 
hypersensitivity reactions by binding to Fc receptors on the membranes of mast cells and 
basophils, causing the cells to degranulate and release histamine. IgD antibodies, along with 
monomeric IgM antibodies, are present in membrane-bound form on mature B-cells. The 
effector functions of soluble IgD antibodies have not yet been identified. 
Antibodies bind to distinct sites on antigens called epitopes, and hence antibodies are 
specific for epitopes and not for entire antigen molecules (1). Antibody/antigen binding depends 
on multiple noncovalent bonds between the amino acids that form the antigen-binding site and 
those that form the epitope. Since the strength of a noncovalent bond is significant only when the 
interacting groups are close, strong antibody/antigen binding is achieved when antigen-binding 
sites and epitopes have a high degree of structural complementarity. An antigen molecule may 
have multiple copies of a given epitope, or may have several different epitopes that induce 
synthesis of antibodies with different antigen-binding sites (Figure 2-2). A population of 
antibodies in which all of the antibodies bind to the same antigen, but subpopulations bind to 
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 structurally different epitopes on the antigen, is referred to as a polyclonal antibody population, 
since each subpopulation is produced by a different B-cell clone. 
2
Antigen X
B-cell 1
B-cell 2
Plasma cell 1
Plasma cell 2
Anti-X,1
Anti-X,2
Epitope 1
Epitope 2
1
2
1
 
Figure 2-2 Induction of polyclonal antibody synthesis by an antigen with 
multiple different epitopes. The role of antigen-specific TH-cells is not shown. 
The relative dimensions of the epitopes, cells, antibodies, and antigens are not 
to scale. 
Antibodies specific for a given epitope are produced when mature B-cells, bearing 
membrane-bound antibodies of the same specificity, encounter the epitope-bearing antigen in the 
blood, lymph, or lymphoid organs (Figure 2-2) (1). Mammalian immune systems can produce 
B-cells of an estimated 108 different specificities, and hence a large number of potential antigens 
can be recognized; most of this diversity is accomplished during B-cell maturation, by random 
rearrangement of the gene segments encoding the variable regions of the light and heavy chains 
that comprise the membrane-bound antibodies. Binding of antigen to membrane-bound 
antibodies causes B-cells to proliferate and then differentiate into memory B-cells and plasma 
cells (antibody-producing cells). Plasma cells begin secreting antibodies about 5-7 days after 
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 mature B-cells are stimulated with antigen, and continue secreting antibodies for 1-2 weeks 
before dying. Memory B-cells live much longer and may confer lifelong immunity to a given 
antigen or antigen-bearing microorganism. 
2.2 Donor-Specific Antibodies in Allograft and Xenograft Rejection 
Donor-specific antibodies mediate hyperacute rejection of ABO-incompatible allografts, 
discordant xenografts, and HLA-incompatible allografts implanted in pre-sensitized recipients 
(20,21). Hyperacute rejection occurs when the transplant recipient has pre-formed antibodies that 
bind to antigens on the graft’s endothelial cells (donor-specific antibodies) (22). Upon initiation 
of blood flow through the graft, antibody/antigen complexes form rapidly and activate the 
complement system via the classical pathway. Endothelial cells are injured when neutrophils, 
attracted by C5a, infiltrate the graft and release lytic enzymes. Formation of the membrane attack 
complex (MAC) may cause additional endothelial cell injury, especially in xenografts whose 
complement regulatory proteins may be incapable of blocking MAC formation by human 
complement components. Platelets adhere to the injured endothelium, aggregate, and stimulate 
thrombin formation. Blood clots form within the graft capillaries and prevent adequate perfusion 
of the graft, causing necrosis of graft cells. Graft function may occur temporarily and decline 
rapidly, or the graft may never function. This reaction typically occurs within 24 hours of 
transplantation (1,20,23). 
Anti-A and anti-B antibodies mediate hyperacute rejection of ABO-incompatible 
allografts; these antibodies bind to A and B blood group antigens found on the surfaces of red 
blood cells, lymphocytes, endothelial cells, and platelets (Table 2-1) (24). The A and B antigens 
are glycoproteins and glycolipids bearing immunodominant carbohydrate epitopes characterized 
by the terminal trisaccharides GalNAc1-3[Fuc1-2]Gal- (A antigen) and Gal1-3[Fuc1-
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 2]Gal- (B antigen) (25). An individual’s blood type is determined by the identities of the blood 
group antigens expressed on his or her tissues; thus type A individuals express A antigens, type 
B individuals express B antigens, type AB individuals express both A and B antigens, and type O 
individuals express neither A nor B antigens. Humans older then 6 months of age continually 
produce antibodies that bind to the blood group antigens that are not expressed on their own 
tissues (26); thus grafts from type A donors are ABO-incompatible with type B and O recipients 
(who produce anti-A antibodies), grafts from type B donors are ABO-incompatible with type A 
and O recipients (who produce anti-B antibodies), and grafts from type AB donors are ABO-
incompatible with type A, B and O recipients (who produce either anti-B or anti-A antibodies, or 
both). Anti-A and anti-B antibody production in humans occurs in response to intestinal bacteria 
bearing the A and B epitopes, and does not require exposure to ABO-incompatible red blood 
cells or other tissues (26). 
Table 2-1 Antibodies Mediating Allograft and Xenograft Rejection 
Graft Type Antigens Antibodies Rejection Type Antibody Production Stimulant 
ABO-incompatible 
allograft 
A 
B 
Anti-A 
Anti-B 
Hyperacute 
Acute 
Chronic 
Intestinal bacteria 
Discordant 
xenograft -Gal Anti--Gal 
Hyperacute 
Acute Intestinal bacteria 
HLA-incompatible 
allograft HLA Anti-HLA 
Hyperacute 
Acute 
Chronic 
Non-self HLA (via blood 
transfusion, pregnancy, 
or previous transplant) 
Anti--Gal antibodies mediate hyperacute rejection of discordant xenografts (grafts from 
New World monkeys or non-primate mammals implanted in humans, chimpanzees, or baboons); 
these antibodies bind to -Gal antigens found on the surfaces of endothelial cells, epithelial cells, 
fibroblasts, smooth muscle cells, and red blood cells in New World monkeys and non-primate 
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 mammals (Table 2-1) (21). The -Gal antigens are glycoproteins and glycolipids bearing 
immunodominant carbohydrate epitopes characterized by the terminal disaccharide Gal1-
3Gal- (-Gal). Humans, chimpanzees and baboons do not express -Gal antigens and hence 
produce anti--Gal antibodies (27,28). Anti--Gal antibody production in humans, chimpanzees, 
and baboons occurs in response to intestinal bacteria bearing -Gal epitopes, and does not 
require exposure to cells or tissues from New World monkeys or non-primate mammals (29). 
Anti-HLA antibodies mediate hyperacute rejection of HLA-incompatible allografts 
implanted in pre-sensitized recipients; these antibodies bind to HLA antigens found on the 
surfaces of most nucleated cells (class I HLA antigens) or on the surfaces of macrophages, 
dendritic cells, B-cells, and activated endothelial cells (class II HLA antigens)(Table 2-1) (20). 
HLA antigens are trans-membrane glycoproteins that present peptides from processed 
endogenous and exogenous antigens to TH-cells and TC-cells (30). In humans, the major class I 
HLA antigens are named HLA-A, HLA-B, and HLA-C, and the major class II HLA antigens are 
named HLA-DR, HLA-DQ, and HLA-DP. The genes that code for the production of HLA 
antigens are highly polymorphic; over 59 different HLA-A alleles, 111 different HLA-B alleles, 
and 37 different HLA-C alleles have been identified (1). Individuals exposed to non-self HLA 
antigens via blood transfusion, pregnancy, or a prior transplant may produce antibodies that bind 
to those HLA antigens, thus becoming pre-sensitized. If such an individual receives a graft 
bearing the same non-self HLA antigens, the pre-formed anti-HLA antibodies may mediate 
hyperacute rejection of the graft. 
Grafts implanted in patients without pre-formed donor-specific antibodies may stimulate 
production of donor-specific antibodies after the transplant (1,23). These grafts may undergo 
acute rejection, which occurs within days or weeks of transplantation, and/or chronic rejection, 
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 which occurs within months or years of transplantation. Acute rejection is mediated by both 
donor-specific T-cells and donor-specific antibodies (22,31). During acute rejection, donor-
specific TC-cells mediate graft cell apoptosis via the perforin/granzyme pathway, and donor-
specific TH-cells produce IFN-, which activates macrophages that release lytic enzymes, nitric 
oxide, and TNF-. Donor-specific antibodies damage the graft endothelial cells and parenchymal 
cells via complement activation as described above, and antibody/antigen complexes involving 
IgG antibodies bind natural killer cells that mediate graft cell apoptosis via the 
perforin/granzyme pathway (antibody-dependent cell-mediated cytotoxicity) (32-34). Acute 
rejection episodes are frequently reversible by prompt and aggressive immunosuppression. 
Conversely, chronic rejection is often unresponsive to immunosuppression and may necessitate 
re-transplantation (22). Chronic rejection is characterized by intimal hyperplasia of the arteries of 
the graft, interstitial fibrosis, atrophy of the graft parenchyma, and declining graft function, and 
is thought to represent a pathologic tissue remodeling response to vascular trauma experienced 
by the graft peri-transplant and post-transplant. The production of donor-specific antibodies post-
transplant correlates strongly with the incidence of chronic rejection (35). 
As of February 2003, the United Network for Organ Sharing (UNOS) reported that 
80,451 individuals were on the waiting list for organ transplantation in the United States; 53,634 
individuals were waiting for kidney transplants, 16,910 individuals were waiting for liver 
transplants, 3,833 individuals were waiting for heart transplants, and 3,827 individuals were 
waiting for lung transplants (36). In 2001, only 23,848 organ transplants were performed, using 
grafts procured from 6,081 deceased donors and 6,526 living donors; 6,190 individuals died 
while on the waiting list (37). Due to this critical shortage of donor organs, many investigators 
are seeking to expand the conditions under which transplantation can be performed. As described 
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 in more detail in the following sections, pre-transplant removal of anti-A and anti-B antibodies 
facilitates ABO-incompatible kidney (38) and liver (39) transplants, and pre-transplant removal 
of anti-HLA antibodies facilitates receipt of HLA-incompatible transplants by pre-sensitized 
recipients (40). Additionally, a good deal of research is devoted to the use of swine organs for 
transplantation in humans, and pre-transplant removal of anti--Gal antibodies is employed as a 
key step in this procedure (21). 
2.2.1 ABO-Incompatible Transplantation With Pre-Transplant Anti-A and Anti-B 
Removal 
a) ABO-Incompatible Kidney Transplantation 
ABO-incompatibility was recognized as a major risk factor in kidney transplantation 
during the early development of transplantation methodology (24). Starzl et al reported a series 
of 7 ABO-incompatible kidney transplants performed at the University of Colorado Medical 
Center, in which two grafts were lost due to hyperacute rejection and were explanted within 
several hours of transplantation (41). Five ABO-compatible, but not ABO-identical, kidney 
transplants were performed by the same group of investigators (4 type O grafts to type A 
recipients, 1 type A graft to a type AB recipient), and all of the grafts showed good early 
function (41). Wilbrandt et al reported a series of 12 ABO-incompatible kidney transplants 
performed at Cleveland Clinic, in which all of the grafts were lost within 19 months and 9 of the 
grafts were lost within 3 months (42). Six of the grafts never functioned and were explanted 
within 17 days. Post-explant examination revealed thrombosis of the renal artery in 9 of the 
grafts. Cook et al reported 25 ABO-incompatible kidney transplants performed accidentally at 
the University of California in Los Angeles (43). Twenty-four of 25 grafts were lost within one 
year of transplantation, and eight of those grafts were lost within 2 weeks of transplantation. 
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 Slapak et al reported the first use of plasma exchange to reverse the rejection of an ABO-
incompatible kidney graft (44). A graft from a type A donor was accidentally implanted in a type 
O recipient, and the recipient experienced four episodes of rejection at 2 days, 17 days, 36 days, 
and 83 days post-transplant. During 3 of the rejection episodes, plasma exchange was performed 
daily for six consecutive days resulting in marked clinical improvement (decreased creatinine 
level and increased urine production). The graft was functioning at 20 months post-transplant. 
Slapak et al then deliberately implanted a type A kidney in a type O recipient, following two 
plasma exchange sessions to reduce the recipient’s anti-A antibody titer (45). The recipient had 
experienced no rejection episodes at 4 months post-transplant. 
Based on the experiences of Slapak and his colleagues, several groups of investigators 
performed ABO-incompatible kidney transplants following pre-transplant removal of anti-A and 
anti-B antibodies from the recipients’ blood. Between 1982 and 1986, Alexandre et al performed 
17 ABO-incompatible living-related donor kidney transplants at University Hospital Saint Luc in 
Belgium (46). Each recipient underwent pre-transplant plasma exchange and splenectomy, and 
15 grafts were functioning at 7 to 58 months post-transplant. Bannet et al performed 6 ABO-
incompatible living-related donor kidney transplants at the Albert Einstein Medical Center, using 
plasma perfusion through Biosynsorb A and B columns to remove anti-A and anti-B antibodies 
pre-transplant (47). (Biosynsorb A and B columns contain synthetic A and B antigens 
immobilized within silica beads, and are no longer commercially available (24).) Five grafts 
were functioning at 2 to 32 months post-transplant, although the anti-A and anti-B titers of each 
recipient returned to pre-transplant levels within two weeks of transplantation. Mendez et al used 
the same columns for pre-transplant anti-A and anti-B removal in a series of 6 ABO-
incompatible living-related donor kidney transplants performed at St. Vincent Medical Center 
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 (48). In each case, the recipient underwent 3 to 5 antibody removal sessions during which whole 
blood was perfused through a Biosynsorb column for 3 to 4 hours. Transplantation was 
performed when the anti-A and anti-B titers were lower than 4. Five of the six grafts were 
functioning at 1 year post-transplant.  
Between 1989 and 1999, Toma et al performed 105 ABO-incompatible living donor 
kidney transplants at Tokyo Women’s Medical University in Japan (49). Before transplantation, 
the recipients’ anti-A and anti-B titers were reduced to 16 or lower via double filtration 
plasmapheresis and plasma perfusion through Biosynsorb A and B columns. At 1, 5, and 10 
years, the patient survival rates were 92%, 92%, and 89%, respectively, and the graft survival 
rates were 77%, 71%, and 51%, respectively. The investigators compared the ABO-incompatible 
patient and graft survival rates to the survival rates obtained in 620 ABO-compatible living 
donor kidney transplants performed at the same center during the same time period. At 1, 5, and 
10 years, the ABO-incompatible graft survival rates were significantly lower than the ABO-
compatible graft survival rates. (At 1, 5, and 10 years, the ABO-compatible graft survival rates 
were 95%, 80%, and 62%, respectively.) However, the investigators found no significant 
difference between the ABO-incompatible and ABO-compatible patient survival rates. The 
percentage of recipients who experienced acute rejection episodes was significantly higher in the 
ABO-incompatible group than in the ABO-compatible group, and the graft survival rates for 
ABO-incompatible recipients who experienced acute rejection episodes were significantly lower 
than the graft survival rates for ABO-incompatible recipients who did not experience acute 
rejection. In most of the ABO-incompatible recipients, the post-transplant anti-A and anti-B 
titers either remained low during the first few months post-transplant (75% of the recipients) or 
rose temporarily and fell spontaneously within several months post-transplant (12% of the 
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 recipients) (50). However, in 9% of the recipients the titers rose rapidly post-transplant and the 
grafts were lost within 2 months. In the remaining 4% of the recipients, the titers rose slowly 
post-transplant and the grafts were lost within 1 year. Additionally, the graft survival rates for 
ABO-incompatible recipients with maximum pre-antibody removal anti-A and anti-B IgG titers 
greater than 128 were significantly lower than the graft survival rates of recipients with 
maximum pre-removal titers less than 16 or between 32 and 64 (51). The minimum pre-
transplant anti-A and anti-B IgG titers, and the maximum and minimum pre-transplant anti-A 
and anti-B IgM titers, did not correlate with graft survival rate. 
b) ABO-Incompatible Liver Transplantation 
ABO-incompatible liver transplants are sometimes performed when the recipient is in 
imminent danger of dying and an ABO-compatible graft is not available. Chui et al reported 7 
ABO-incompatible liver transplants performed at Royal Prince Alfred Hospital in Australia 
between 1986 and 1996 (52). All of the recipients presented with fulminant hepatic failure and 
had class 4 UNOS status (i.e. had life expectancies of seven days without transplantation). No 
attempt was made to reduce the recipients’ anti-A and anti-B titers pre-transplant. Two grafts 
were lost within 1 month and one was lost within 11 months, while 3 grafts were functioning 
well at 52 months. (One recipient died with a functioning graft.) Bjoro et al reported 10 ABO-
incompatible liver transplants performed in the Nordic countries (Denmark, Finland, Norway, 
and Sweden) between 1990 and 2001, again performed without pre-transplant reduction of the 
recipients’ anti-A and anti-B titers (53). The graft survival rate at 1 year was 30%, compared to a 
1-year graft survival rate of 75% for 143 ABO-identical grafts transplanted at the same centers. 
Recently, Hanto et al reported much better results in a series of 14 ABO-incompatible liver 
transplants performed between 1992 and 2001 at the University of Cincinnati Medical Center 
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 (39). Each recipient underwent pre-transplant plasma exchange to reduce anti-A and anti-B titers, 
post-transplant plasma exchange to maintain low anti-A and anti-B titers for 2 weeks post-
transplant, and splenectomy. The 1 and 5-year graft survival rates were 71.4% and 61.2%, 
respectively, and none of the grafts were lost due to rejection (graft loss was only due to recipient 
death unrelated to graft rejection). At 2 weeks post-transplant, 7 recipients had anti-A or anti-B 
IgG titers greater then 16 but did not experience antibody-mediated rejection. The investigators 
speculated that these recipients were exhibiting accommodation, a phenomenon in which a graft 
is not rejected and continues to function despite the presence of anti-graft antibodies and 
complement (54). 
c) ABO-Incompatible Bone Marrow Transplantation 
In contrast to ABO-incompatible solid organ transplantation, ABO-incompatible bone 
marrow transplantation is performed regularly (55). In bone marrow transplantation, ABO-
incompatibility is characterized as minor, major, or bidirectional. Minor ABO-incompatible bone 
marrow transplants involve the transplant of marrow from type O donors into type A, B, or AB 
recipients; in this situation, donor-derived antibodies and B-cells may bind to A and B antigens 
on recipient cells. Major ABO-incompatible bone marrow transplants involve the transplant of 
marrow from type A, B, or AB donors into type O recipients; in this situation, recipient-derived 
antibodies may bind to A and B antigens on donor cells. Finally, bidirectional ABO-
incompatible bone marrow transplants involve the transplant of marrow from type A donors into 
type B recipients or from type B donors into type A recipients; in this situation, both of the 
above-described activities may take place. To facilitate minor ABO-incompatible bone marrow 
transplants, donor plasma is removed from the bone marrow pre-transplant via centrifugation. To 
facilitate major ABO-incompatible bone marrow transplants, recipients either undergo pre-
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 transplant plasma exchange or the donor marrow is depleted of red blood cells pre-transplant. 
Both of the above-described procedures are performed to facilitate bidirectional bone marrow 
transplants. 
Stussi et al reported a series of 361 ABO-identical, 98 minor ABO-incompatible, 96 
major ABO-incompatible, and 17 bidirectional ABO-incompatible bone marrow transplants 
performed at University Hospital of Zurich and University Hospital of Basel in Switzerland 
between 1980 and 1998 (55). The investigators found no significant differences in the incidence 
of moderate to severe graft-versus-host disease among the four groups. Additionally, there was 
no effect of ABO-incompatibility on the relapse rate or on the time to platelet and neutrophil 
engraftment. However, bidirectional ABO-incompatible recipients had significantly higher 
mortalities than the other 3 groups of recipients.   
2.2.2 Xenotransplantation With Pre-Transplant Anti--Gal Removal 
Current efforts in xenotransplantation are focused on the transplantation of swine organs 
into humans (21). Non-primates with suitably sized organs, such as pigs, are available in large 
numbers and do not engender the risk of lethal virus transmission associated with transplantation 
of non-human primate organs into humans. As discussed in section 2.2, anti--Gal antibodies 
mediate hyperacute rejection of grafts from non-primate mammals implanted in humans, 
chimpanzees, or baboons. (Baboons are frequently used in animal models of pig-to-human 
xenotransplantation.) Several groups have used plasma exchange or blood or plasma perfusion 
through -Gal-containing immunoadsorption columns to remove anti--Gal antibodies from 
baboon blood or plasma. Kozlowski et al performed in vivo removal of baboon anti--Gal 
antibodies by perfusing whole blood or plasma through columns containing synthetic -Gal 
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 antigens immobilized within silica beads (56). Post-immunoadsorption anti--Gal IgM and IgG 
antibody levels were less than 20% of pre-immunoadsorption levels using either whole blood or 
plasma perfusion, but whole blood perfusion was associated with significant hemolysis and the 
need for post-immunoadsorption red blood cell transfusions. Taniguchi et al performed in vivo 
removal of baboon anti--Gal antibodies by perfusing plasma through columns containing 
synthetic -Gal antigens immobilized within macroporous glass beads (57). Anti-pig IgM and 
IgG antibody levels were reduced significantly via immunoadsorption, but rebounded within 1 
week of the final immunoadsorption session despite pharmacologic immunosuppression and 
splenectomy. Prior to pig-to-baboon kidney transplants, Kobayashi et al used double filtration 
plasmapheresis (DFPP) to reduce the baboons’ anti-pig IgM and IgG antibody levels to below 
15% of pre-DFPP levels (58). Hyperacute rejection of the pig kidneys was prevented, but the 
grafts were lost within 1 week due to severe humoral rejection. Immunohistochemical 
examination of the explanted grafts revealed IgM and IgG antibodies bound to the graft 
endothelial cells. Cooper et al perfused baboon blood through donor-specific pig kidneys to 
remove baboon anti--Gal antibodies prior to pig-to-baboon heart transplants (7). None of the 
transplanted hearts functioned for longer than 5 days.  
Unfortunately, acute loss of the graft due to antibody-mediated rejection is a common 
outcome in pig-to-primate transplants, despite prevention of hyperacute rejection via pre-
transplant anti--Gal removal or complement inhibition (59). Currently, several groups have 
focused on the production of transgenic pigs that do not express -Gal antigens. Lai et al 
produced miniature pigs with 1 allele of the -1,3galactosyltransferase locus knocked out (60), 
and Phelps et al produced pigs with both alleles knocked out (61). (The enzyme -
1,3galactosyltransferase adds the terminal Gal1-3 residues to oligosaccharide precursors to 
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 form the -Gal antigens (62).) If consistent production of healthy pigs completely lacking -Gal 
antigens is achieved, organs from these pigs may be used for pig-to-primate transplantation and 
pre-transplant removal of anti--Gal may be unnecessary. 
2.2.3 Implantation of HLA-Incompatible Allografts in Pre-Sensitized Recipients With 
Pre-Transplant Anti-HLA Removal 
Pre-sensitized organ transplantation candidates may wait years for a suitable donor organ 
to become available. (A suitable organ would be one from a donor who does not express the 
HLA antigens to which the recipient’s anti-HLA antibodies bind.) Pre-transplant anti-HLA 
removal has been used to de-sensitize these candidates and expedite transplantation. Palmer et al 
decreased the anti-HLA titers and panel-reactive antibody (PRA) scores in 7 kidney transplant 
recipients by performing plasma perfusion through immunoadsorption columns containing 
immobilized protein A (63). Each patient had a positive cross-match with his or her donor prior 
to immunoadsorption, and a negative cross-match post-immunoadsorption. One graft never 
functioned and another was lost at 1 year post-transplant, but the remaining 5 grafts were 
functioning at 3 to 23 months post-transplant. Ross et al performed plasma perfusion through 
protein A-containing immunoadsorption columns to reduce the PRA scores of 5 kidney 
transplant candidates whose scores had been greater than 80% for 1.75 to 5 years (64). One 
patient lost the graft at 8 weeks post-transplant, but the other 4 patients had functioning grafts at 
3 to 34 months post-transplant. Most recently, surgeons at Johns Hopkins Hospital in Baltimore 
instituted a protocol in which plasma exchange is used to de-sensitize kidney transplant 
candidates who have positive cross-matches to living donors (40). Eighteen kidney transplant 
recipients underwent this procedure between 1998 and 2001, and on average 3 plasma exchange 
treatments were required to attain a negative cross-match between each recipient and his or her 
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 donor. One graft was lost due to donor non-compliance, but the other 17 grafts were functioning 
at 1 to 44 months post-transplant. 
2.3 Self-Antigen-Binding Antibodies in Autoimmune Disease 
Autoimmune diseases involve antibody-mediated or cell-mediated immune responses 
directed against self-antigens (1). Autoimmune diseases are classified as organ-specific (directed 
against a self-antigen isolated within a single organ) or systemic (directed against one or several 
self-antigens distributed within multiple organs and tissues). Examples of organ-specific 
autoimmune diseases include myasthenia gravis, Goodpasture syndrome, and idiopathic 
thrombocytopenic purpura (ITP), while examples of systemic autoimmune diseases include 
rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) (Table 2-2). The American 
Association of Blood Banks (AABB) and the American Society for Apheresis (ASFA) have 
classified autoimmune diseases based on the effectiveness of therapeutic apheresis (plasma 
exchange or immunoadsorption) in treating the diseases (65). For category I diseases, such as 
myasthenia gravis and Goodpasture syndrome, therapeutic apheresis is standard and acceptable 
as a primary therapy. For category II diseases, such as hemophilia with inhibitors, ITP, and RA, 
therapeutic apheresis is generally accepted but is considered to be supportive to other primary 
treatments. For category III diseases, such as SLE and hemolytic disease of the newborn, 
existing evidence is insufficient to establish the efficacy of therapeutic apheresis. 
Myasthenia gravis (66) and Goodpasture syndrome (67) are customarily treated using 
plasma exchange in addition to immunosuppression and other pharmacological treatments. Anti-
acetylcholine receptor antibodies mediate myasthenia gravis; these antibodies bind to 
acetylcholine receptors (AchR) on the motor end plates of muscles (Table 2-2) (1). Anti-
AchR/AchR binding inhibits muscle activation and induces complement-mediated destruction of 
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 acetylcholine receptors, and myasthenia gravis patients experience varying degrees of skeletal 
muscle weakness involving the facial, limb, and respiratory muscles (68). Plasma exchange is 
most often used in patients experiencing myasthenic crisis, characterized by acute weakness of 
the respiratory muscles and often requiring mechanical ventilation (68). In a retrospective study 
of 27 myasthenic crisis patients treated with plasma exchange, over 70% of the patients were 
extubated within 2 weeks (69). Benny et al used plasma perfusion through protein-A containing 
immunoadsorption columns to treat 12 myasthenia gravis patients, and 9 patients demonstrated 
improvement in symptom scores following treatment (3). During each immunoadsorption 
procedure approximately 8.4 L of plasma was treated, and each patient underwent 2 or 3 
procedures. The mean percent reduction in anti-AchR titer achieved via immunoadsorption was 
68%. 
Anti-glomerular basement membrane antibodies mediate Goodpasture syndrome; these 
antibodies bind to type IV collagen within the basement membranes (GBM) of the kidney 
glomeruli and the lung alveoli (Table 2-2) (2,70). Anti-GBM/GBM binding causes 
glomerulonephritis and lung hemorrhage. Patients with Goodpasture syndrome typically undergo 
daily plasma exchange treatments for several weeks using 5% albumin as the replacement fluid 
(67). Levy et al reported the long-term outcome for 71 Goodpasture syndrome patients treated 
using plasma exchange and immunosuppression (71). In patients with pre-treatment creatinine 
concentrations less than 500 mol/L, the patient and renal function survival rates were 100% and 
95%, respectively, at 1 year post-treatment, and 94% and 94%, respectively, at 5 years post-
treatment. In patients with pre-treatment creatinine concentrations greater than 500 mol/L, the 
patient and renal function survival rates were 83% and 82%, respectively, at 1 year post-
treatment, and 80% and 50%, respectively, at 5 years post-treatment.  
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Table 2-2 Antibodies Mediating Autoimmune Diseases 
Disease Antigens/Tissues Affected Antibodies 
Antibody 
Removal 
Indicated? 
AABB and 
ASFA 
Category 
Myasthenia gravis Acetylcholine receptors (AchR) Anti-AchR Yes I 
Goodpasture 
syndrome 
Glomerular 
basement 
membranes 
(GBM) 
Anti-GBM Yes I 
Hemophilia with 
inhibitors 
Factor VIII 
Facto IX 
Anti-Factor VIII 
Anti-Factor IX Yes II 
Idiopathic 
thrombocytopenic 
purpura 
Platelets Anti-platelet Yes II 
Rheumatoid 
arthritis IgG antibodies 
Anti-IgG 
(rheumatoid 
factors) 
Yes II 
Systemic lupus 
erythematosus 
DNA 
Histone 
Red blood cells 
(RBC) 
Platelets 
Anti-DNA 
Anti-histone 
Anti-RBC 
Anti-platelet 
Possibly III 
Hemolytic disease 
of the newborn 
A antigens 
B antigens 
IgG anti-A 
IgG anti-B Possibly III 
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 Hemophilia with inhibitors (72), ITP (73), and RA (73) are treated using plasma 
perfusion through protein A-containing immunoadsorption columns in addition to 
immunosuppression and other pharmacological treatments. The Immunosorba® protein A-
containing immunoadsorption column (Fresenius HemoCare, Inc.) is FDA-approved for the 
treatment of hemophilia with inhibitors, and the Prosorba® protein A-containing column 
(Fresenius HemoCare, Inc.) is FDA-approved for the treatment of ITP and RA. Anti-Factor VIII 
and anti-Factor IX antibodies mediate hemophilia with inhibitors; these antibodies bind to 
infused Factor VIII and Factor IX in hemophilia patients and render coagulation factor 
replacement therapy ineffective (Table 2-2) (72). The Malmö Treatment Model for the induction 
of tolerance in hemophilia (with inhibitors) patients was developed in the early 1980s, and 
involves plasma perfusion through protein A-containing immunoadsorption columns and 
administration of cyclophosphamide and intravenous immunoglobulin (74). Freiburghaus et al 
reported that 16 of 23 hemophilia patients treated with this protocol achieved tolerance (defined 
as the elimination of anti-Factor VIII and anti-Factor IX antibodies and the normalization of the 
half-lives of infused Factor VIII and Factor IX) (74). Jansen et al used plasma perfusion through 
immunoadsorption columns containing immobilized anti-human immunoglobulin to treat 10 
hemophilia (with inhibitors) patients (75). The anti-Factor VIII antibody titer was reduced by 50-
97% following each immunoadsorption session. Seven patients achieved remission, defined by 
sustained absence of anti-Factor VIII antibodies. 
Anti-platelet antibodies mediate idiopathic thrombocytopenic purpura (ITP); anti-
platelet/platelet binding causes phagocytosis of platelets by macrophages bearing Fc receptors 
(Table 2-2). Snyder et al used plasma perfusion through Prosorba® columns to treat 72 ITP 
patients with pre-immunoadsorption platelet counts less than 50,000/l (5). In 18 patients 
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 platelet counts increased to greater than 100,000/l, and in 15 patients platelet counts increased 
to between 50,000/l and 100,000/l. Christie at al used the same columns to treat 10 ITP 
patients, and platelet counts in 6 patients increased to twice the pre-immunoadsorption counts 
(76). 
Anti-IgG antibodies of IgM isotype (rheumatoid factors) mediate rheumatoid arthritis 
(RA) (Table 2-2) (1). Anti-IgG/IgG complexes are deposited in the joints of RA patients, 
causing chronic inflammation and synovial hypertrophy. Felson et al performed a randomized, 
controlled, double-blind trial to evaluate the efficacy of plasma perfusion through Prosorba® 
columns in the treatment of refractory RA (77). Thirty-two percent of the Prosorba®-treated 
patients experienced improvement as defined by the American College of Rheumatology (ACR) 
response criteria, compared to only 11.4% of the control patients. 
An array of self-antigen-binding antibodies of different specificities mediate systemic 
lupus erythematosus (SLE), and SLE patients experience diverse symptoms ranging from non-
specific symptoms such as fatigue and fever to organ-specific symptoms such as arthritis, skin 
rash, glomerulonephritis, and pleurisy (Table 2-2) (1,73). Unfortunately, most controlled trials 
evaluating the efficacy of therapeutic apheresis in the treatment of SLE have shown no clinical 
benefit (73). Wei at al performed a randomized, controlled, double-blind trial to evaluate the 
efficacy of plasma exchange in the treatment of mild SLE (78). Twenty patients underwent either 
6 4-L plasma exchanges or 6 control procedures over a 2-week period. Although IgG, IgM, and 
IgA antibody levels were reduced by the plasma exchanges, patients in the control and plasma 
exchange groups experienced the same degree of clinical improvement. Lewis et al performed a 
randomized, controlled trial comparing the efficacy of standard therapy (prednisone and 
cyclophosphamide) to that of standard therapy plus plasma exchange in the treatment of severe 
 25
 SLE (79). Plasma exchange did not reduce the incidence of renal failure or death. To date, 
randomized, controlled trials evaluating the efficacy of immunoadsorption in SLE treatment have 
not been reported, but several anecdotal studies have shown promising results. Braun et al used 
plasma perfusion through protein A-containing Immunosorba® columns to treat 8 SLE patients 
who were resistant to standard therapy (80). Seven patients achieved remission quantified by a 
decrease in the SLE activity measure (SLAM), and 2 patients who had dialysis-dependent renal 
insufficiency pre-immunoadsorption recovered renal function post-immunoadsorption. Using the 
same columns, Palmer et al treated 10 patients with rapidly progressive glomerulonephritis and 
acute renal failure, and 9 patients regained renal function post-immunoadsorption (81).  
2.4 Therapeutic Antibody Removal 
In the United States, therapeutic antibody removal is usually achieved non-selectively, 
via plasma exchange, or semi-selectively, via plasma perfusion through immunoadsorption 
columns containing immobilized protein A (65). Immunoadsorption columns containing 
immobilized anti-human immunoglobulin are also commercially available and are used outside 
the United States (82). In addition, several groups of investigators have developed bead-based 
and membrane-based antibody filters that use immobilized antigens to achieve selective antibody 
removal. Each of these antibody removal methods will be discussed in more detail in the 
following sections. 
2.4.1 Plasma Exchange 
Plasma exchange involves withdrawal of venous blood from a patient, separation of the 
plasma from the cellular blood components via centrifugation or membrane filtration, and return 
of the cellular blood components to the patient along with albumin solution or donor plasma as 
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 replacement fluid (9). Three to 4.5 L of plasma (approximately 1 to 1.5 times the total volume of 
plasma in an average human) is removed and exchanged with replacement fluid during a typical 
plasma exchange session, and sessions are generally performed 2-4 times per week. The 
preferred replacement fluid is 5% albumin, but donor plasma is used for patients at risk of 
bleeding or requiring daily plasma exchanges for several weeks. Continuous flow centrifuges 
operate at inlet blood flow rates of 60-110 ml/min and outlet plasma flow rates of 35-60 ml/min, 
and hence 3 L of plasma can be removed within 90 min (83). Centrifuges separate blood 
components according to their specific gravities, and the concentration of pathogenic antibodies 
in the removed plasma is approximately equal to the concentration in the plasma before 
plasma/cell separation. Membrane-based plasma separators operate at inlet blood flow rates of 
50-200 ml/min and outlet plasma flow rates of 15-50 ml/min, and hence 3 L of plasma can be 
removed within 100 min (84). Membrane-based plasma filters separate blood components based 
on the ability of each component to permeate the membranes, and some proteins (especially high 
molecular weight proteins like IgM antibodies) may be present at lower concentrations in the 
removed plasma than in the plasma before plasma/cell separation (84). 
2.4.2 Protein A Columns 
Two protein A-containing immunoadsorption columns, the Prosorba® column and the 
Immunosorba® column, are commercially available through Fresenius HemoCare (Redmond, 
WA) (85). As discussed in section 2.3, the columns are FDA-approved for the treatment of 
rheumatoid arthritis and idiopathic thrombocytopenic purpura (Prosorba®) and hemophilia with 
inhibitors (Immunosorba®). The Prosorba® column contains 200 mg of purified protein A 
immobilized within 123 g of silica beads, and one Prosorba® column can bind about 0.6 g of 
IgG antibodies at saturation (12). One treatment consists of perfusing up to 2 L of plasma 
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 through the column at a flow rate of 10-20 ml/min. A single treatment using a Prosorba® column 
causes a small reduction in the concentration of IgG antibodies in the patient’s blood, and the 
efficacy of Prosorba®-based treatment is thought to be based on the removal of immune 
complexes and on subtle immunomodulatory effects rather than on the removal of IgG 
antibodies (10). The recommended course of treatment for RA is one Prosorba® perfusion per 
week for 12 weeks, and the recommended course of treatment for ITP is 2-3 Prosorba® 
perfusions per week for 2-3 weeks (86). 
The Immunosorba® column contains purified protein A immobilized within Sepharose® 
beads following cyanogen bromide activation of the beads, and one Immunosorba® column can 
bind about 1.2 g of IgG antibodies at saturation (12). Two Immunosorba® columns are used 
intermittently during each treatment; while plasma is perfused through one column, adsorbed 
antibodies are eluted from the other to prepare it for re-use when the first column becomes 
saturated. One treatment consists of perfusing up to 10 L of plasma through the columns at a 
flow rate of 10-20 ml/min (85). A single treatment using Immunosorba® columns causes a 
substantial reduction in the concentration of IgG antibodies in the patient’s blood, due to the 
“unlimited” capacity of the columns and the large volume of plasma treated (10). A set of 2 
Immunosorba® columns can be re-used up to 20 times by the same patient (10). 
2.4.3 Anti-Human Immunoglobulin Columns 
Ig-Therasorb®, an immunoadsorption column containing immobilized anti-human 
immunoglobulin, is commercially available through PlasmaSelect (Teterow, Germany) (82). The 
anti-human immunoglobulin is obtained by immunizing sheep with human antibodies, and Ig-
Therasorb® columns bind human IgG (all subclasses), IgM, and IgA antibodies. Each column 
contains anti-human immunoglobulin immobilized within 150 ml of Sepharose® beads, and one 
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 Ig-Therasorb® column can bind approximately 4 g of IgG antibodies at saturation (12). Like the 
Immunosorba® system, the Ig-Therasorb® system employs 2 columns that are used 
intermittently during each treatment. One treatment consists of perfusing up to 8 L of plasma 
through the columns at a flow rate of 20-25 ml/min (75). 
2.4.4 Bead-Based Selective Antibody Filters 
Several groups of investigators have developed bead-based antibody filters that use 
immobilized antigens to achieve selective antibody removal (Table 2-3). As discussed in section 
2.2.1, Biosynsorb columns (no longer available), containing synthetic A and B antigens 
immobilized within silica beads, were developed for the removal of anti-A and anti-B antibodies 
from plasma and were used to facilitate ABO-incompatible kidney transplants (48,49,87). Each 
column contained 75 g of silica beads with 0.7 mol of synthetic A or B antigens immobilized 
within each gram of beads (88). A thin coating of porous polystyrene was applied to the beads to 
allow whole blood perfusion of the columns (88). For the same application, Rieben at al 
developed columns called BioSorbent A and BioSorbent B, containing synthetic A and B 
antigens immobilized within macroporous glass beads (89). As a preliminary step toward the 
development of columns for selective anti-HLA removal, DeVito et al immobilized human 
HLA-A2 antigens within Sepharose® beads and showed that incubation of the beads with 
plasma significantly reduced anti-HLA-A2 titers in plasma samples from 3 individuals (90). 
Human HLA-A2 antigens were isolated from human spleen cells and purified using immobilized 
monoclonal anti-HLA-A2 antibodies, but the authors surmised that obtaining large quantities of 
HLA antigen variants in the future may be simpler due to advances in recombinant DNA 
technology. 
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 Table 2-3 Bead-Based Selective Antibody/Ligate Filters 
Immobilized 
Antigen/Ligand 
Removed 
Antibody/Ligate Matrix 
Blood/Plasma 
Compatible References 
A 
B 
Anti-A 
Anti-B Silica beads 
Blood 
Plasma (48,49,87) 
A Anti-A Macroporous glass beads Plasma (89) 
HLA Anti-HLA Sepharose® Plasma (90) 
-Gal Anti--Gal Sepharose® Plasma (91) 
-Gal Anti--Gal Macroporous glass beads Plasma (57) 
-Gal Anti--Gal Silica beads Blood Plasma (8) 
AchR Anti-AchR Not reported Plasma (92) 
Heparinase Heparin Agarose Blood (93) 
Anti-2-
microglobulin 2-microglobulin Agarose Blood (94) 
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 Several groups have focused on developing bead-based filters for selective anti--Gal 
removal. Gerber at al immobilized synthetic -Gal disaccharide and/or trisaccharide antigens 
within Sepharose® beads via polyacrylamide spacers, and found that beads containing a mixture 
of immobilized disaccharides and trisaccharides achieved the best removal of anti--Gal from 
human plasma (91). Taniguchi et al immobilized synthetic -Gal disaccharide antigens within 
macroporous glass beads via polyacrylamide spacers, and used columns containing these beads 
to remove anti-pig antibodies from baboon plasma in vivo (57). Xu et al immobilized 2 different 
synthetic -Gal trisaccharides within silica beads, and found that beads containing trisaccharide 
type 2 (Gal1-3Gal1-4GlcNAc) removed more anti--Gal from human plasma than beads 
containing trisaccharide type 6 (Gal1-3Gal1-4Glc) (8). 
Takamori et al synthesized part of the -subunit of the human acetylcholine receptor 
(AchR) and immobilized the synthetic peptide within beads (matrix material not reported) for the 
selective removal of anti-AchR antibodies from human plasma (92). Treatment of myasthenia 
gravis patients using plasma perfusion through AchR peptide-containing columns reduced the 
patients’ anti-AchR antibody titers and caused clinical improvement in the patients. 
Ameer et al developed a novel device for blood purification that allows both plasma/cell 
separation and bead-based plasma treatment to occur within a single device (93-95). The vortex-
flow plasmapheretic reactor (VFPR) consists of a solid rotating inner cylinder inside a hollow 
stationary outer cylinder, and blood flows through the annular compartment between the two 
cylinders. A microporous membrane divides the annular compartment into an inner cell 
compartment and an outer plasma compartment. Blood enters the VFPR and plasma flows across 
the membrane into the plasma compartment, which contains either heparinase or anti-2-
microglobulin immobilized within agarose beads. After flowing through the plasma 
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 compartment, the treated plasma is recombined with the cellular blood components and returned 
to the patient. The rotating inner cylinder creates Taylor vortices that fluidize the beads. The 
heparinase-containing VFPR is intended for heparin neutralization, and the anti-2-
microglobulin-containing VFPR is intended for selective removal of 2-microglobulin.  
2.4.5 Membrane-Based Selective Antibody Filters 
Several groups of investigators have developed membrane-based antibody filters that use 
immobilized antigens to achieve selective antibody removal (Table 2-4). Our own group 
immobilized A and B antigens on the inner fiber walls of cellulose hollow fiber dialysis 
membranes to produce filters for anti-A and anti-B removal (14). Filters with 0.9 m2 of blood 
contacting surface area significantly reduced the anti-A and anti-B titers of up to 900 ml of type 
O whole human blood. Karoor et al immobilized synthetic -Gal trisaccharide antigens on the 
inner fiber walls of cellulose hollow fiber dialysis membranes, and within the pores of 
polysulfone and nylon hollow fiber microfiltration membranes, to produce filters for anti--Gal 
removal (96). Nylon microfiltration membranes containing -Gal antigens immobilized via 
spacer molecules had an anti--Gal IgM-binding capacity of 89 mg of IgM per ml of membrane 
or about 2.1 g of IgM per cm2 of internal surface area. Singh et al immobilized insulin on the 
inner fiber walls of cellulose hollow fiber dialysis membranes to produce filters for anti-insulin 
removal, and removed up to 98% of anti-insulin antibodies from 200 ml samples of human 
plasma (the surface area of the filters was not reported) (16). Larue at al immobilized human IgG 
and human serum albumin (HSA) on the inner fiber walls of cellulose hollow fiber dialysis 
membranes to produce filters for anti-IgG and anti-HSA removal (17). To demonstrate the 
selectivity of antibody removal by the filters, the filters were used to remove anti-IgG and anti-
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 HSA antibodies from a dog immunized with human IgG and HSA. The IgG-containing filter, 
used first, caused the anti-IgG titer to fall from 128 to 2 but caused no reduction in the anti-HSA 
titer. The HSA-containing filter, used second, caused the anti-HSA titer to fall from 256 to 2. 
To produce filters for IgG removal, Klein et al immobilized protein A within the pores of 
polysulfone hollow fiber membranes after coating the membranes with hydroxyethylcellulose 
(HEC) (97). At saturation, the membranes bound 16 mg of IgG per ml of membrane or about 1.3 
g of IgG per cm2 of internal surface area. Similarly, Charcosset et al immobilized protein A 
within the pores of polysulfone/HEC hollow fiber membranes (98). The membranes bound 8.8 
mg of IgG per ml of membrane or about 0.5 g of IgG per cm2 of internal surface area. 
Two groups have developed heparin filters comprised of hollow fiber dialysis membranes 
with heparin-binding ligands immobilized on the inner fiber walls: Yang et al used immobilized 
protamine to remove heparin from canine blood during ex vivo studies (18), and Ma et al used 
immobilized poly(L-lysine) to remove heparin from phosphate-buffered saline and bovine blood 
(19). The heparin-binding capacity of the poly(L-lysine)-containing dialysis membranes was 
0.54 g/cm2.  
Soltys et al immobilized anti-low-density lipoprotein (LDL) antibodies within the pores 
of microporous polyvinylidene diflouride flat sheet membranes to produce filters for LDL 
removal (99). The LDL-binding capacity of the membranes was 2.0 mg of LDL per ml of 
membrane or about 0.18 g of LDL per cm2 of internal surface area. 
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 Table 2-4 Membrane-Based Selective Antibody/Ligate Filters 
Immobilized 
Antigen/Ligand 
Removed 
Antibody/Ligate 
Membrane 
Material/Type 
Blood/Plasma 
Compatible References 
A 
B 
Anti-A 
Anti-B Cellulose/Dialysis Blood (14,15) 
-Gal Anti--Gal 
Cellulose/Dialysis 
Polysulfone/ 
Microfiltration 
Nylon/ 
Microfiltration 
Blood (96) 
Insulin Anti-insulin Cellulose/Dialysis Blood (16) 
Human albumin 
(HSA) Anti-HSA Cellulose/Dialysis Blood (17) 
Protein A IgG Polysulfone/ Microfiltration Not reported (97) 
Protein A IgG Polysulfone/ Microfiltration Not reported (98) 
Protamine Heparin Cellulose/Dialysis Blood (18) 
Poly(L-lysine) Heparin Poly(ethylene-vinyl alcohol) Blood (19) 
Anti-low-density 
lipoprotein (LDL) LDL 
Polyvinylidene 
diflouride Plasma (99) 
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 2.5 Specific Antibody Filters (SAFs) 
The specific antibody filters (SAFs) under development in our laboratory are comprised 
of hollow fiber dialysis membranes with antigens, specific for targeted antibodies, immobilized 
on the inner fiber walls (14,15). Each SAF contains several thousand fibers connected in parallel, 
and is similar in construction to a hollow fiber hemodialyzer. For extracorporeal therapeutic 
antibody removal, the SAF will be incorporated within a simple perfusion loop similar to the 
loops used for hemodialysis (Figure 2-3). Blood will be withdrawn from the patient, perfused 
through the SAF, and returned to the patient. As blood flows through the fiber lumens, the 
targeted antibodies will bind to the immobilized antigens and become trapped within the SAF. 
Separation of the plasma from the cellular blood components will not be required. The 
parameters relevant to SAF-based antibody removal, and their characteristic magnitudes, are 
listed in Table 2-5. 
SAF:
Number of fibers: N
Length: L
Inner radius: a
Binding capacity: csi
Q
Q
Patient:
Blood volume: V
Ab concentration: cbl
Pre-removal Ab concentration: cbli  
Figure 2-3 Schematic depicting SAF-based therapeutic 
antibody removal. Ab: antibody. 
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 The clinical usefulness of SAF-based antibody removal will be assessed based on the 
post-removal concentration of self-antigen-binding or donor-specific antibodies in the patient’s 
blood (compared to the pre-removal concentration) and the length of time required to accomplish 
the concentration reduction, assuming that the SAF is appropriately biocompatible and non-
toxic. As discussed in Chapter 1.0, the primary focus of the research reported in this dissertation 
is to identify the primary mechanisms that control antibody transport within the SAF, and to use 
this information to guide the choice of design and operational parameters that maximize the 
SAF-based antibody removal rate (and hence minimize the length of time required for SAF-
based antibody removal). In Chapters 4.0 and 5.0, we will describe the analytical and 
experimental studies we performed to approach these goals. To date we have not performed 
extensive studies aimed at maximizing the SAF antibody-binding capacity (and hence 
minimizing the post-removal blood antibody concentration), although we have performed a 
“proof of concept” study (reported in Chapter 3.0) showing that a SAF containing immobilized 
A and B blood group antigens can remove a significant fraction of the anti-A and anti-B 
antibodies from about 1 L of whole human blood. 
However, based on the expected magnitudes of the SAF antibody-binding capacity, the 
pre-removal concentration of pathogenic antibodies in the patient’s blood, and the 
antibody/antigen equilibrium dissociation constant, we can estimate the post-removal blood 
antibody concentration for a SAF with a reasonable blood-contacting surface area.  Since 
antibody/antigen binding is reversible, during a SAF-based antibody removal session the 
concentration of pathogenic antibodies in the patient’s blood will fall, and the concentration of 
antibodies bound to the SAF fibers will rise, until the rate of antibody/antigen association is 
equal to the rate of antibody/antigen dissociation (i.e. until equilibrium is reached). The 
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 Langmuir adsorption isotherm equation relates the bound antibody concentration at equilibrium 
to the blood antibody concentration at equilibrium (107): 
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where cbeq (g/cm2) is the bound antibody concentration at equilibrium, cbleq (g/ml) is the blood 
antibody concentration at equilibrium, csi (g/cm2) is the antibody-binding capacity of the SAF 
(defined as the mass of antibodies bound to the SAF fibers at saturation per unit of blood 
contacting surface area), and Kd (g/ml) is the antibody/antigen equilibrium dissociation 
constant. The concentration of bound antibodies at equilibrium can be expressed in terms of the 
pre-removal blood antibody concentration (cbli) and the equilibrium blood antibody 
concentration: 
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where V (ml) is the patient’s total blood volume and SA (cm2) is the blood-contacting surface 
area of the SAF.  Substituting equation (2-2) into equation (2-1), we can solve for cbleq/cbli as a 
function of cbli: 
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We can use equation (2-3) to estimate the ratio of the post-removal to the pre-removal 
blood antibody concentration, for a given pre-removal blood antibody concentration, SAF 
antibody-binding capacity, SAF surface area, and antibody/antigen equilibrium dissociation 
constant. To use equations (2-1) and (2-3) we must assume that the populations of antibodies and 
immobilized antigens are homogeneous, so that Kd is the same for every antibody/antigen pair. 
Clinically, the antibody population will be polyclonal and hence heterogeneous, and the 
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 population of immobilized antigens will be heterogeneous if the immobilization technique allows 
multiple orientations of the immobilized antigens. We must also assume that the time required 
for a substantial increase in the blood antibody concentration due to antibody synthesis and 
antibody transport from the extravascular to the intravascular compartment is small compared to 
the time required to conduct the antibody removal session. This assumption has been validated 
by comparison of the measured percent removals of IgG, IgM, and IgA antibodies during plasma 
exchange to the percent removals predicted when antibody synthesis and extravascular to 
intravascular antibody transport are neglected (108). 
We used equation (2-3) to estimate the ratio of the post-removal to the pre-removal blood 
antibody concentration, as a function of the pre-removal concentration, for a patient treated using 
a SAF with a surface area of 5 m2 and an antibody-binding capacity of 1 g/cm2 (Figure 2-4). 
An equilibrium dissociation constant of 1.5 g/ml was used based on the reported dissociation 
constants for antibody/antigen systems with either the antibodies or the antigens immobilized 
(Table 2-5) (1,106,107). We chose 1 g/cm2 as an order of magnitude estimate of the antibody-
binding capacity of the SAF, since the approximate surface concentration of a monolayer of IgG 
molecules is 0.6 g/cm2 (101,102), and since several investigators have developed affinity 
membranes with antibody-binding capacities between 0.5 and 2 g/cm2 (2.4.5) (96-98). 
Clinically, the pre-removal blood antibody concentration will most likely lie between 0.5 and 70 
g/ml, based on the reported concentrations of anti--Gal antibodies in human and baboon blood 
(56,96) and anti-malaria antibodies in human blood (104) (Table 2-5).  
For patients with pre-removal blood antibody concentrations less than 10 g/ml, the 
estimated post-removal blood antibody concentration will be less than 30% of the pre-removal 
concentration, assuming that the antibody removal session continues until equilibrium is reached 
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 (Figure 2-4). However, for patients with pre-removal concentrations greater than 10 g/ml, the 
estimated post-removal concentration will be between 30% and 90% of the pre-removal 
concentration. To treat these patients, we may need to use 2 SAFs intermittently during each 
antibody-removal session, perfusing the patient’s blood through one SAF while bound antibodies 
are eluted from the other to prepare it for re-use when the first SAF becomes saturated. This 
technique is currently used in the Immunosorba® and Ig-Therasorb® antibody removal systems 
(12), but may be more difficult to use in the SAF system since the SAF will need to be emptied 
of whole blood (instead of plasma) before the antibodies are eluted. 
We also used equation (2-3) to estimate the ratio of the bound antibody concentration at 
equilibrium to the antibody-binding capacity of the SAF, as a function of the pre-removal blood 
antibody concentration (again for a patient treated using a SAF with a surface area of 5 m2 and an 
antibody-binding capacity of 1 g/cm2, and for an antibody/antigen equilibrium dissociation 
constant of 1.5 g/ml) (Figure 2-5). For patients with pre-removal blood antibody 
concentrations less than 1.5 g/ml (i.e. less than Kd), the concentration of bound antibodies at 
equilibrium is small compared to the antibody-binding capacity of the SAF. For patients with 
pre-removal blood antibody concentrations greater than Kd, the concentration of bound 
antibodies at equilibrium approaches the antibody-binding capacity of the SAF. Therefore, the 
SAF antibody-binding capacity required to reduce the blood antibody concentration by a given 
percentage is not linearly proportional to the pre-removal blood antibody concentration. For 
example, using a 5 m2 SAF, the capacity required to reduce the blood antibody concentration to 
30% of the pre-removal concentration is 0.4 g/cm2 if the pre-removal concentration is 1 g/ml, 
and is 1 g/cm2 if the pre-removal concentration is 10 g/ml. 
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Figure 2-4 Theoretical reduction in self-antigen-binding or donor-
specific antibody concentration following SAF-based antibody removal, 
assuming that the removal session continues until equilibrium is 
reached. 
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Figure 2-5 Theoretical concentration of bound antibodies relative to the 
SAF antibody-binding capacity following SAF-based antibody removal, 
assuming that the removal session continues until equilibrium is reached. 
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 Table 2-5 Characteristic Magnitudes of Parameters Relevant to SAF-Based Antibody Removal 
SAF Geometry and Binding Capacity References 
Number of fibers N 6000-32,000 (100) 
Fiber length L (cm) 25 (100) 
Fiber inner radius a (cm) 0.01 (100) 
Blood-contacting surface area SA (m2) 1-5 (100) 
Antibody-binding capacity csi  (nmol/m2 or 
g/cm2) 
IgG: 40 nmol/m2 (.6 g/cm2) 
IgM: 12 nmol/m2 (1.1 g/cm2) 
(101,102) 
Patient Parameters and Blood Flow Rate  
Total blood volume V (L) 3.5-5.5 (103) 
Concentration of donor-specific or self-
antigen-binding antibodies in blood cbli 
(g/ml) 
IgG: 0.5-40 
IgM: 5-70 (59,96,104) 
Blood flow rate Q (ml/min) 50-500 (100) 
Antibody and Antibody/Antigen Parameters  
Antibody diffusivity D (cm2/s) IgG, water, 22 ºC: 3.9*10
-7 
IgM, water, 22 ºC: 1.4*10-7 (105) 
Association rate constant kf (L/mol*s or 
ml/g*s) 
104-106 L/mol*s  
(10-5-10-2 ml/g*s) (106,107) 
Equilibrium dissociation constant Kd  
(mol/L or g/ml) 
10-9-10-7 mol/L  
(0.15-90 g/ml) (106,107) 
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 3.0 ANTI-A AND ANTI-B REMOVAL FROM HUMAN BLOOD USING SPECIFIC 
ANTIBODY FILTERS CONTAINING IMMOBILIZED A AND B ANTIGENS 
End stage renal disease (ESRD), characterized by complete and irreversible kidney 
failure, causes retention of metabolic wastes, water, and salts, and eventually causes death unless 
renal function is replaced using hemodialysis or kidney transplantation (109). Compared to long-
term hemodialysis, kidney transplantation provides an enhanced quality of life, enhanced 
longevity (110), and lower healthcare costs, and hence ESRD patients with high probabilities of 
post-transplant survival (as determined by standardized pre-transplant evaluations (111)) are 
designated as candidates for living donor or cadaveric donor kidney transplantation (111,112). 
Living donor kidney transplantation is preferred to cadaveric donor transplantation because 
living donor grafts exhibit higher survival rates than do cadaveric donor grafts, even when the 
living donors are not genetically related to the transplant recipients (113). Thus a kidney 
transplant candidate with a suitable related or unrelated living donor receives the living donor 
kidney, provided that the donor is ABO-compatible with the candidate and the candidate does 
not have pre-formed antibodies that bind to the donor’s HLA antigens (111). As discussed in 
Chapter 2.0, ABO-incompatible kidney transplantation is rarely performed since pre-formed 
anti-A and anti-B antibodies in the recipient’s blood may mediate hyperacute rejection of an 
ABO-incompatible donor kidney (24,38). A kidney transplant candidate with an otherwise 
suitable, but ABO-incompatible, living donor does not receive the living donor kidney, but 
instead is listed with the United Network for Organ Sharing (UNOS), along with over 50,000 
other kidney transplant candidates (36), and waits an average of 5 years for an ABO-compatible 
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 cadaveric donor kidney to become available (114). While waiting the transplant candidate spends 
an average of 9-12 hours per week undergoing maintenance hemodialysis (109). The survival 
rates for ESRD patients on hemodialysis are 78% at 1 year, 63% at 2 years, and 33% at 5 years 
(115).  
Based on the frequencies of ABO blood groups in the United States, an estimated 36% of 
potential living donor-kidney transplant candidate pairs are ABO-incompatible (116,117). Thus 
the number of kidney transplant candidates who receive living donor kidneys might be raised 
significantly by the development of techniques to facilitate ABO-incompatible kidney 
transplantation. Several groups of investigators have performed ABO-incompatible kidney 
transplants following pre-transplant removal of anti-A and anti-B antibodies from the recipients’ 
blood (46-49). The largest series of such transplants was performed in Japan: between 1989 and 
1999, Toma et al performed 105 ABO-incompatible living donor kidney transplants at Tokyo 
Women’s Medical University (49). Before transplantation, the recipients’ anti-A and anti-B titers 
were reduced to 16 or lower via double filtration plasmapheresis and plasma perfusion through 
Biosynsorb A and B columns. At 1 and 5 years post-transplant, the graft survival rates were 77% 
and 71%, respectively. At 3 years post-transplant, the graft survival rates for ABO-compatible 
living donor and cadaveric donor kidney transplants performed in the United States are 81-85% 
and 70%, respectively (113). Since the 3 to 5 year graft survival rates are similar for ABO-
incompatible living donor transplants (performed according to the Toma protocol) and ABO-
compatible cadaveric donor transplants, and since the survival rates for ESRD patients on 
hemodialysis are discouraging, a kidney transplant candidate who has an ABO-incompatible 
living donor may prefer to receive the ABO-incompatible living donor kidney (with treatment 
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 according to the Toma protocol) rather than wait for an ABO-compatible cadaveric donor kidney 
to become available.  
The methods that are currently available for extracorporeal anti-A and anti-B removal 
include plasma exchange and plasma perfusion through immunoadsorption columns containing 
immobilized protein A or anti-human immunoglobulin (9-13). The Biosynsorb A and B columns 
used by Toma et al (49), which contain synthetic A and B antigens and selectively remove anti-A 
and anti-B antibodies from plasma, are no longer commercially available (24). The goal of this 
study was to assess the feasibility of selectively removing anti-A and anti-B antibodies directly 
from whole human blood using specific antibody filters (SAFs) containing immobilized protein-
based A and B antigens. We fabricated SAFs by immobilizing A and B antigens on the lumenal 
surfaces of the hollow fibers comprising commercially available hemodialyzers. Initially, we 
performed a series of paired antibody removal experiments to compare the anti-A and anti-B 
removal accomplished by SAFs containing immobilized A and B antigens to the non-specific 
removal accomplished by control SAFs (unmodified hemodialyzers or SAFs containing 
immobilized bovine serum albumin). We performed preliminary biocompatibility testing by 
comparing the SC5b-9 generation induced by the SAFs containing immobilized A and B 
antigens to the SC5b-9 generation induced by the control SAFs. We then assessed the antibody-
binding capacity of a SAF containing immobilized A and B antigens by sequentially circulating 
100 ml blood samples through the SAF until the titers of a newly introduced blood sample were 
not reduced. Finally, we purified the A and B antigens by removing a low molecular weight 
component that did not bind anti-A and anti-B antibodies, and assessed the antibody-binding 
capacity of a SAF containing immobilized purified A and B antigens. 
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 3.1 Methods 
3.1.1 Acquisition of Protein-Based A and B Antigens 
The commercially available product Neutr-AB® (Dade Behring, Switzerland) was used 
as the source of protein-based A and B antigens. Neutr-AB® contains A antigen-bearing proteins 
obtained from pig intestinal mucosa, and B antigen-bearing proteins obtained from horse 
intestinal mucosa (118).  
3.1.2 SAF Fabrication 
Gambro (Lakewood, CO) 400 HG hemodialyzers were used as SAF modules. Each 
module contained approximately 7742 Hemophan® fibers of 0.02 cm nominal inner diameter 
and 18.5 cm length, providing a blood-contacting surface area of 0.9 m2 (100). Neutr-AB® or 
bovine serum albumin (BSA) (Sigma Chemical Co., St. Louis, MO) was immobilized on the 
lumenal surfaces of the fibers using a modified version of the cyanogen bromide activation 
method developed by Axen et al (119). Unless otherwise noted, chemicals were obtained from 
Sigma Chemical Company (St. Louis, MO). During the following fiber activation steps, the 
blood and shell compartments of the SAF module were connected in series using tygon tubing. 
Both compartments of the module were first rinsed copiously with de-ionized water. To swell the 
fibers, 3.5 L of 0.2 N NaOH was circulated through the module for five hours, on ice, at 136 
ml/min. The module was flushed with 3.5 L of 0.1 M sodium bicarbonate buffer, pH 8.5 
(henceforth called bicarbonate buffer), at 225 ml/min and at 4 ˚C. An activating solution of 16 g 
CNBr in 200 ml of 0.2 N NaOH was circulated through both compartments at 136 ml/min, on 
ice, for 1.5 hours. The activating solution pH was kept above 11.0 by the addition of cold 10 N 
NaOH. The module was flushed with 3.5 L of de-ionized water and 3.5 L of bicarbonate buffer, 
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 at 225 ml/min and at 4 ˚C. Excess fluid was removed from the module using filtered compressed 
air.  
The shell compartment was then filled with bicarbonate buffer and closed. One hundred 
ml of a 7-mg/ml antigen solution (Neutr-AB® or BSA dissolved in bicarbonate buffer) was 
circulated through the blood compartment at 77 ml/min, at room temperature, overnight (at least 
12 hours). Both compartments were drained, and samples were collected from the blood and 
shell compartments for measurement of antigen concentration. The blood and shell 
compartments were again connected in series and the SAF was washed three times, by 
circulating 500 ml of bicarbonate buffer through the SAF at 136 ml/min for one hour (each 
wash). Excess fluid was removed from the SAF using filtered compressed air, and the SAF was 
stored at 4 ˚C until use.  
The mass of antigen immobilized within the SAF was calculated by subtracting the mass 
of antigen recovered by the washings, the mass of antigen in the antigen solution after the 
immobilization step, and the mass of antigen in the shell compartment after the immobilization 
step, from the mass of antigen initially in the antigen solution. The mass of antigen in each 
solution was calculated using the solution volume and the protein concentration, determined by 
measuring the absorbance at 280 nm with a UV/VIS spectrophotometer (Perkin Elmer, Norwalk, 
CT). 
3.1.3 Neutr-AB® Purification 
Aqueous gel filtration chromatography revealed that Neutr-AB® contained two 
significant protein fractions with molecular weights of approximately 35,000 and 6000 Da. One 
hundred and ten ml of Neutr-AB® was placed within a section of Spectra/Por® dialysis tubing 
with a 12,000-14,000 Da molecular weight cutoff (Thomas Scientific, Swedesboro, NJ) and 
 46
 dialyzed extensively against 0.1 M sodium bicarbonate buffer, pH 8.5. The concentration of the 
recovered high molecular weight (purified) Neutr-AB® was 2.4 mg/ml. A 0.7-mg/ml sample of 
low molecular weight Neutr-AB® was recovered from the dialysate. 
As described below, the antigenic quality of the purified Neutr-AB was higher than that 
of the un-purified Neutr-AB® (3.1.8, 3.2.4). A SAF containing immobilized purified Neutr-AB® 
was fabricated as described above (3.1.1), except that the concentration of the antigen solution 
(purified Neutr-AB® in bicarbonate buffer) at the beginning of the immobilization step was 2.4 
mg/ml instead of 7 mg/ml. As described below (3.1.12, 3.2.5), the antibody-binding capacity of 
this SAF was compared to that of a SAF containing immobilized un-purified Neutr-AB®, also 
fabricated using a 2.4-mg/ml antigen solution (un-purified Neutr-AB® in bicarbonate buffer).  
3.1.4 Blood Acquisition 
Type O fresh blood was drawn from healthy, non-pregnant, consenting donors over age 
18, with the approval of the University of Pittsburgh Institutional Review Board. Fresh blood 
was drawn no more than 2 hours before the initiation of the antibody removal experiment, and 
was anticoagulated using heparin (Elkins-Sinn, Inc., Cherry Hill, NJ) at a concentration of 10 
U/ml. Overfilled bags of type O and type A banked blood were obtained from the Central Blood 
Bank of Pittsburgh and stored at 4	C until use. Banked blood was anticoagulated using citrate 
phosphate dextrose (CPD). Plasma for blood typing, titer measurement, and cross-matching was 
obtained by centrifugation of blood samples for 15 minutes, at 1380xG, in a bench-top centrifuge 
(Fisher Scientific, Pittsburgh, PA).  
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 3.1.5 Blood Typing 
Blood was typed according to the standard blood bank procedure (120). For each blood 
sample to be typed, plasma was obtained via centrifugation and 100 l of plasma was added to 
each of two 12 x 75 mm disposable glass test tubes. Fifty l of type A1 reagent red blood cells 
(Immucor Inc., Norcross, GA) was added to one test tube, and 50 l of type B reagent red blood 
cells was added to the other test tube. The tubes were mixed gently, centrifuged for 1 minute at 
1380xG, and examined for red cell agglutination. Plasma from type A blood caused 
agglutination of type B red cells only; plasma from type B blood caused agglutination of type A1 
red cells only; plasma from type O blood caused agglutination of both type A1 and type B red 
cells; and plasma from type AB blood caused agglutination of neither type A1 nor type B red 
cells.  
3.1.6 Cross-matching 
For experiments requiring the use of blood samples from multiple donors, all blood 
samples were cross-matched according to the standard blood bank procedure (120). The 
following procedure was performed for each pair of blood samples (called sample 1 and sample 
2) to be cross-matched. Plasma was obtained from each blood sample via centrifugation. A 2-4% 
suspension of washed red blood cells was obtained from each blood sample by washing red 
blood cells (obtained via centrifugation) 3 to 5 times in 0.9% NaCl, then suspending 200 l of 
washed red blood cells in 4.8 ml of 0.9% NaCl. One hundred l of plasma from sample 1 was 
added to one 12 x 75 mm disposable glass test tube, and 100 l of plasma from sample 2 was 
added to a second test tube.  Fifty l of the 2-4% suspension of red cells from sample 1 was 
added to the test tube containing plasma from sample 2, and 50 l of red cells from sample 2 was 
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 added to the test tube containing plasma from sample 1. The tubes were mixed gently, 
centrifuged for 1 minute at 1380xG, and examined for red cell agglutination. If no agglutination 
was observed, 100 l of antibody enhancer (LISS, Immucor Inc., Norcross, GA) was added to 
each tube, and the tubes were mixed gently and incubated at 37 °C for 15 minutes. The tubes 
were centrifuged for 1 minute at 1380xG, and examined again for red cell agglutination. If no 
agglutination was observed, the cells in each tube were washed 3 times with 0.9% NaCl, and the 
supernatant was decanted completely after the third wash. One hundred l of anti-human 
globulin (Immucor Inc., Norcross, GA) was added to each tube. The tubes were mixed gently, 
centrifuged for 1 minute at 1380xG, and examined for red cell agglutination. If no agglutination 
was observed, the 2 samples had a negative cross-match and could be used safely in the same 
experiment. To check the validity of the cross-match, 50 l of Coombs control cells (Immucor 
Inc., Norcross, GA) was added to each tube. The tubes were mixed gently, centrifuged for 1 
minute at 1380xG, and examined for red cell agglutination. If the control cells failed to 
agglutinate, the cross-match was repeated. 
3.1.7 Measurement of Anti-A and Anti-B Antibody Titers 
Anti-A and anti-B antibody titers were measured using plasma serial dilutions and the 
standard blood bank hemagglutination assay used for blood typing (120). Using this method the 
titer was assumed to reflect the concentration of IgM anti-A and anti-B antibodies only. For each 
blood sample to be assayed, plasma was obtained via centrifugation and serial dilutions of the 
plasma were prepared in 0.9% NaCl. Each diluted sample was assayed for the ability to 
agglutinate type A1 or type B reagent red blood cells, as described above (3.1.5). The anti-A titer 
was taken as the reciprocal of the largest dilution that agglutinated type A1 reagent red blood 
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 cells, and the anti-B titer was taken as the reciprocal of the largest dilution that agglutinated type 
B reagent red blood cells. If an undiluted plasma sample did not agglutinate type A1 or type B 
reagent red blood cells, the blood sample was assigned an anti-A or anti-B titer of 0.  
3.1.8 Antigenic Quality Measurement 
A hemagglutination inhibition assay was used to compare the antigenic qualities of the 
un-purified Neutr-AB®, the purified (high molecular weight) Neutr-AB®, and the low molecular 
weight Neutr-AB®. The antigenic quality of each form of Neutr-AB® was quantified by 
determining the minimum Neutr-AB® concentration required to completely inhibit the 
agglutination of type A1 or type B reagent red blood cells by human plasma, after mixing equal 
volumes of Neutr-AB® and plasma. For the un-purified Neutr-AB®, samples with total protein 
concentrations between 0.01 mg/ml and 5 mg/ml were prepared using 0.9% NaCl as the diluent. 
For the purified Neutr-AB®, samples with total protein concentrations between 0.001 mg/ml and 
0.5 mg/ml were prepared. The low molecular weight Neutr-AB® was not diluted. For each 
sample of Neutr-AB®, 200 l of Neutr-AB® was added to 200 l of plasma in a 12 x 75 mm 
disposable glass test tube. The tube was mixed gently and incubated at room temperature for 5 
minutes. The plasma/Neutr-AB® solution was tested for the ability to agglutinate type A1 and 
type B reagent red blood cells, as described above (3.1.5). The anti-A and anti-B inhibition 
concentrations were taken as the minimum concentrations of Neutr-AB® required to inhibit the 
agglutination of type A1 and type B reagent red blood cells.  
3.1.9 In Vitro Perfusion Loop 
In vitro antibody removal experiments were performed using the simple perfusion loop 
shown in Figure 3-1. The loop consisted of a glass blood reservoir, a Masterflex peristaltic pump 
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 (Cole-Parmer Instrument Company, Vernon Hills, IL), a glass bead flow meter (Cole-Parmer 
Instrument Company, Vernon Hills, IL), and a SAF. The components of the loop were connected 
using tygon tubing. The SAF was oriented horizontally as shown in Figure 3-1. Blood was 
pumped solely through the blood compartment of the SAF, and ultrafiltrate was collected from 
the shell compartment and returned to the reservoir. The entire loop, including both the blood 
and shell compartments of the SAF, was flushed with 0.9% NaCl prior to each experiment. Air 
was removed from the system during priming with blood. 
Pump
SAF
Flow Meter
Blood 
Reservoir
 
Figure 3-1  Perfusion loop used for in vitro antibody 
removal experiments. 
3.1.10 Initial Paired Antibody Removal Experiments 
The first series of antibody removal experiments was performed to compare the anti-A 
and anti-B removal accomplished by SAFs containing immobilized A and B antigens (SAF-AB) 
to the non-specific removal accomplished by control SAFs (unmodified hemodialyzers or SAFs 
containing immobilized bovine serum albumin, SAF-Ctrl). SAFs containing immobilized A and 
B antigens and control SAFs were tested under identical conditions. A 250 ml sample of type A 
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 or O fresh or banked whole blood (from one donor) was obtained as described above (3.1.4). 
One hundred ml of the blood was circulated through the SAF containing immobilized A and B 
antigens at 100 ml/min for 30 minutes. Aliquots were taken from the reservoir every 15 minutes 
and the anti-A and anti-B titers were measured. One hundred ml of the blood was then circulated 
through the control SAF at 100 ml/min for 30 minutes, and aliquots were taken from the 
reservoir every 15 minutes for titer measurement. For each experiment, pre-perfusion, post-SAF-
AB perfusion, and post-SAF-Ctrl perfusion plasma samples were saved to allow comparison of 
SAF-AB- and SAF-Ctrl-induced complement activation. 
3.1.11 Biocompatibility Testing 
Following each of the initial antibody removal experiments described above (3.1.10), pre-
perfusion, post-SAF-AB perfusion, and post-SAF-Ctrl perfusion plasma samples were assayed 
for complement activation product SC5b-9 concentration using commercially available 
immunoassay kits (Quidel Corporation, San Diego, CA). The assays were performed in the 
Biomaterials and Tissue Engineering Laboratory, directed by William Wagner, in the McGowan 
Institute for Regenerative Medicine at the University of Pittsburgh.  
3.1.12 SAF Capacity Experiments 
The second series of antibody removal experiments was performed to estimate the 
antibody-binding capacities of SAFs containing immobilized A and B antigens (SAF-AB) or 
immobilized purified A and B antigens (SAF-ABp). SAFs containing immobilized A and B 
antigens and control SAFs (SAF-Ctrl) were tested under identical conditions. Up to 3 L of type 
O banked whole blood (from up to 6 different donors) was obtained as described above (3.1.4), 
and all of the blood samples used in each experiment were cross-matched prior to the experiment 
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 as described above (3.1.6). Blood from each donor was split so that half could be circulated 
through the SAF-AB and half could be circulated through the SAF-Ctrl. (When testing the SAFs 
containing immobilized purified A and B antigens, blood from each donor was split into thirds so 
that 1/3 could be circulated through the SAF-AB, 1/3 could be circulated through the SAF-ABp, 
and 1/3 could be circulated through the SAF-Ctrl). Capacity experiments were performed by 
sequentially circulating multiple 100 or 150 ml samples of blood through the SAF at a flow rate 
of 100 ml/min. When the anti-A and anti-B titers of a given blood sample dropped to 2 or below, 
the entire flow loop was drained, including both the blood and shell compartments of the SAF, 
and a new blood sample was circulated through the SAF. The SAF was not washed between 
successive blood samples to avoid measurement of an artificially high capacity caused by 
removal of some of the bound antibodies during the washing. This procedure was repeated until 
the titer of a newly introduced blood sample was not reduced. The capacity of the SAF was taken 
as the volume of blood processed before titer reduction ceased. 
3.2 Results 
3.2.1 Initial Paired Antibody Removal Experiments 
Anti-A and anti-B antibodies were successfully removed from 100 ml of freshly drawn 
type O whole human blood by a SAF containing approximately 99 mg of immobilized A and B 
antigens (SAF-AB) (Figure 3-2). After 30 minutes, the SAF-AB reduced the anti-A titer from 8 
to 1 and the anti-B titer from 16 to 1. Anti-A and anti-B antibodies were not measurably removed 
from 100 ml of blood (from the same donor) by a control SAF containing immobilized bovine 
serum albumin (BSA). After 30 minutes, the control SAF had not measurably reduced the anti-A 
titer or the anti-B titer. 
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Figure 3-2 Anti-A and anti-B removal from 100 ml of freshly drawn type 
O whole human blood using a SAF with approximately 99 mg of 
immobilized A and B antigens (SAF-AB). Non-specific anti-A and anti-B 
removal using a control SAF with immobilized BSA (SAF-Ctrl) is also 
shown. Closed symbols: SAF-AB. Open symbols: SAF-Ctrl. 
Six paired antibody removal experiments were performed using blood from 6 different 
donors, and in each experiment the SAF-AB accomplished a larger anti-A and anti-B titer 
reduction than did the SAF-Ctrl (Table 3-1). The mass of A and B antigens immobilized within 
each SAF-AB ranged from 69 to 99 mg, with a mean of 86 mg. The SAF-ABs accomplished a 
mean anti-A titer reduction of 70% and a mean anti-B titer reduction of 94%, while the SAF-
Ctrls accomplished a mean anti-A titer reduction of 0% and a mean anti-B titer reduction of 
33%. Using the paired t-test, the percent anti-A titer reduction and anti-B titer reduction 
accomplished by the SAF-ABs was statistically greater than the percent reduction accomplished 
by the SAF-Ctrls (p < 0.005). 
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 Table 3-1 Antibody Removal During Initial Paired Antibody Removal Experiments 
Trial Blood Source 
Control 
Filter 
Initial 
Anti-A 
Titer 
Initial 
Anti-B 
Titer 
Final 
Anti-A 
Titer 
(SAF-AB) 
Final 
Anti-B 
Titer 
(SAF-AB) 
Final 
Anti-A 
Titer 
(SAF-
Ctrl) 
Final 
Anti-B 
Titer 
(SAF-
Ctrl) 
1 Fresh type O 
SAF-
BSA 8 16 1 1 8 16 
2 Fresh type O 
SAF-
BSA 16 8 8 2 16 4 
3 Bank type A 
SAF-
BSA N/A 8 N/A 0 N/A 4 
4 Fresh type O Dialyzer 16 8 2 0 16 4 
5 Fresh type O Dialyzer 8 8 4 0 8 8 
6 Bank type O Dialyzer 16 16 4 1 16 8 
3.2.2 Biocompatibility Testing 
In each paired antibody removal experiment, the SC5b-9 concentration increased 
following both SAF-AB perfusion and SAF-Ctrl perfusion (Table 3-2). (SC5b-9 concentration 
data from trial six were not obtained due to a technical error.) The SAF-ABs induced a mean 
increase in SC5b-9 concentration of 500%, while the SAF-Ctrls induced a mean increase in 
SC5b-9 concentration of 800%. Using the paired t-test, the percent increase in SC5b-9 
concentration induced by the SAF-ABs was not statistically different from the percent increase 
induced by the SAF-Ctrls (p > 0.1).  
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 Table 3-2 Complement Activation During Initial Paired Antibody Removal Experiments 
Trial 
Initial SC5b-9 
Concentration 
(ng/ml) 
Final SC5b-9 Concentration 
(ng/ml) (SAF-AB) 
Final SC5b-9 Concentration 
(ng/ml) (SAF-Ctrl) 
1 26.4 80.7 84.1 
2 14.2 39.6 26.2 
3 15.5 38.0 107.8 
4 1.2 14.5 22.2 
5 10.9 100.7 152.3 
3.2.3 SAF Capacity Experiment 1: Capacity of a SAF Containing Immobilized A and B 
Antigens 
Anti-A and anti-B antibodies were successfully removed from 4 100 ml samples of type 
O banked human blood by a SAF containing approximately 100 mg of immobilized A and B 
antigens (Figure 3-3). The anti-A titers of the first three blood samples were reduced from 64 to 
1 (98%), 64 to 1 (98%), and 64 to 2 (97%), respectively. The anti-A titer of the fourth sample 
was reduced from 16 to 4 (75%), and the anti-A titers of the fifth and sixth samples were not 
measurable reduced. The anti-B titers of the first four samples were reduced from 8 to zero 
(100%), and the anti-B titers of the fifth and sixth samples were reduced from 8 to 2 (75%) and 8 
to 1 (88%), respectively. Anti-A and anti-B antibodies were not measurably removed from 6 100 
ml samples of type O banked human blood (from the same donors) by a control SAF containing 
immobilized BSA.  The anti-A and anti-B titers of each sample were not measurably reduced 
(data not shown). 
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Figure 3-3 Anti-A and anti-B removal from 6 100 ml samples of type O 
banked human blood using a SAF with approximately 100 mg of 
immobilized A and B antigens (SAF-AB). Zero percent titer reduction is 
indicated by the absence of a bar. 
3.2.4 Purification of A and B Antigens (Neutr-AB®) 
The concentration of un-purified Neutr-AB® required to inhibit the agglutination of type 
A1 and type B reagent red blood cells by human plasma varied from 0.05 to 4 mg/ml, depending 
on the plasma sample used to perform the hemagglutination inhibition assay (3.1.8) (Table 3-3). 
The concentration of purified Neutr-AB® required to inhibit agglutination by the same plasma 
samples varied from 0.01 to 0.25 mg/ml. The assay was performed using 3 different plasma 
samples, with initial anti-A and anti-B titers of 0 and 64 (type A), 64 and 32 (type O, 1), and 32 
and 32 (type O, 2). Neither the un-purified Neutr-AB® inhibition concentration nor the purified 
Neutr-AB® inhibition concentration increased with increasing initial anti-A or anti-B titer. The 
sample-to-sample variation in the inhibition concentration was likely due to sample-to-sample 
variation in the affinities of the anti-A and anti-B antibodies for Neutr-AB®, or sample-to-
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 sample variation the concentration of IgG anti-A and anti-B antibodies. At a concentration of 0.7 
mg/ml, the low molecular weight Neutr-AB® was unable to inhibit the agglutination of type A1 
or type B red cells by any of the tested plasma samples. 
Table 3-3 Standard and Purified Neutr-AB® Inhibition Concentrations 
 Un-purified Neutr-AB® 
Purified (High MW) Neutr-
AB® Low MW Neutr-AB® 
Plasma 
Sample 
Anti-A 
Inhibition 
Conc. 
(mg/ml) 
Anti-B 
Inhibition 
Conc. 
(mg/ml) 
Anti-A 
Inhibition 
Conc. 
(mg/ml) 
Anti-B 
Inhibition 
Conc. 
(mg/ml) 
Anti-A 
Inhibition 
Conc. 
(mg/ml) 
Anti-B 
Inhibition 
Conc. 
(mg/ml) 
A N/A 0.3 N/A 0.025 N/A > 0.7 
O, 1 0.2 0.05 0.025 0.01 > 0.7 > 0.7 
O, 2 0.75 4 0.05 0.25 > 0.7 > 0.7 
For each plasma sample used, the un-purified Neutr-AB® inhibition concentration was 
higher than the purified Neutr-AB® inhibition concentration (Figure 3-4). The un-purified 
Neutr-AB® anti-A inhibition concentration was between 8 and 15 times the purified Neutr-AB® 
anti-A inhibition concentration, and the un-purified Neutr-AB® anti-B inhibition concentration 
was between 5 and 16 times the purified Neutr-AB® anti-A inhibition concentration. 
3.2.5 SAF Capacity Experiment 2: Capacity of a SAF Containing Immobilized Purified A 
and B Antigens 
Anti-A and anti-B antibodies were successfully removed from 6 150 ml samples of type 
O banked human blood by a SAF containing approximately 40 mg of immobilized purified A 
and B antigens (purified Neutr-AB®) (Figure 3-5). The anti-A titers of the first through sixth 
blood samples were reduced from 32 to 1 (97%), 32 to 2 (94%), 32 to 2 (94%), 16 to 1 (94%), 16 
to 2 (88%), and 8 to 2 (75%), respectively. The anti-B titers of the first through sixth blood 
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 samples were reduced from 32 to 0 (100%), 16 to 0 (100%), and 8 to 0 (100%), 4 to 0 (100%), 4 
to 0 (100%), 8 to 1 (88%), respectively. Anti-A and anti-B antibodies were successfully removed 
from one 150 ml sample of type O banked human blood by a SAF containing approximately 40 
mg of immobilized un-purified A and B antigens (un-purified Neutr-AB®). The anti-A and anti-
B titers of the first sample were reduced from 32 to 8 (75%) and 32 to 4 (88%), respectively. The 
anti-A and anti-B titers of the second through sixth samples were not measurably reduced. Anti-
A and anti-B antibodies were not measurably removed from 6 150 ml samples of type O banked 
human blood (from the same donors) by a control SAF containing immobilized BSA.  The anti-
A and anti-B titers of each sample were not measurably reduced (data not shown).  
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Figure 3-4 Ratio of the un-purified Neutr-AB® inhibition concentration to the 
purified Neutr-AB® inhibition concentration, for three different plasma 
samples with initial anti-A and anti-B titers of 0 and 64 (type A), 64 and 32 
(type O, 1), and 32 and 32 (type O, 2). 
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Figure 3-5 Anti-A and anti-B removal from 6 150 ml samples of type O banked 
human blood using a SAF with approximately 40 mg of immobilized un-purified 
A and B antigens (SAF-AB) and a SAF with approximately 40 mg of 
immobilized purified A and B antigens (SAF-ABp). Zero percent titer reduction 
is indicated by the absence of a bar. 
3.3 Discussion 
Specific antibody filters (SAFs) containing immobilized protein-based A and B antigens 
selectively removed anti-A and anti-B antibodies directly from whole human blood. In an initial 
series of six paired antibody removal experiments, the anti-A and anti-B removal accomplished 
by SAFs containing immobilized A and B antigens (SAF-AB) was significantly higher than the 
non-specific anti-A and anti-B removal accomplished by control SAFs (SAF-Ctrl). Additionally, 
the percent increase in SC5b-9 concentration induced by the SAF-ABs was not statistically 
different from the percent increase induced by the SAF-Ctrls. 
A SAF containing approximately 100 mg of immobilized A and B antigens reduced the 
anti-A and anti-B titers of 400 ml of type O whole human blood by 75 to 100%. Assuming that 
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 the SAF antibody-binding capacity is linearly proportional to the blood-contacting surface area, a 
SAF with approximately 12 times the surface area of the prototype SAF (i.e. with a blood-
contacting surface area of about 11 m2) would be required to significantly reduce the anti-A and 
anti-B titers of 5 L of whole human blood (the blood volume of an average adult patient). 
However, purifying the A and B antigens prior to immobilization improved the SAF antibody-
binding capacity. A SAF containing approximately 40 mg of immobilized purified A and B 
antigens reduced the anti-A and anti-B titers of 900 ml of type O whole human blood by 75 to 
100%, implying that a SAF with only 6 times the blood-contacting surface area of the prototype 
SAF (i.e. with a blood-contacting surface area of about 5.5 m2) would be required to significantly 
reduce the anti-A and anti-B titers of 5 L of whole human blood.  
The SAF antibody-binding capacity may possibly be further improved by using synthetic 
A and B antigens instead of naturally occurring protein-based A and B antigens (such as those 
that comprise Neutr-AB®). Synthetic antigens can be obtained at near 100% purity, and can be 
synthesized on spacer arms of varying lengths to allow optimization of the distance between the 
antigen and the membrane. Reactive groups on the spacer arms would allow oriented 
immobilization of the synthetic antigens, instead of the randomly oriented immobilization that 
occurs when protein-based antigens are immobilized via numerous available primary amines on 
the proteins. Finally, SAFs could be fabricated containing only A antigens or only B antigens, 
since the only situation in which both anti-A and anti-B removal would be necessary would be 
the transplant of a type AB kidney into a type O patient. Based on the frequencies of ABO blood 
groups in the United States, only 1% of potential living donor-kidney transplant candidate pairs 
would involve a type AB donor and a type O recipient (116,117). Based on these considerations, 
our continuing SAF development work will be focused on the use of synthetic A and B antigens. 
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 During SAF-based antibody removal, antibody-antigen complexes formed on the lumenal 
surfaces of the SAF fibers will activate the complement system via the classical pathway, and the 
degree of complement activation may be greater than the degree produced during other 
extracorporeal therapies like hemodialysis and cardiopulmonary bypass (121). The preliminary 
biocompatibility testing we performed did not show increased complement activation by the 
SAFs with immobilized A and B antigens compared to the control SAFs. In our continuing 
studies we will perform more extensive biocompatibility testing, using both in vitro and in vivo 
experimental formats. However, we do not expect complement activation to be a significant 
problem since SAF-based antibody removal will be performed only during the peri-transplant 
period, and will not be performed chronically like hemodialysis. Also, Sakhrani et al used whole 
blood perfusion through Biosynsorb columns to remove anti-A or anti-B antibodies prior to 
ABO-incompatible kidney transplants (thus presumably activating the complement system via 
the classical pathway), and reported that the side effects were mild in most of the treated patients 
(87). 
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 4.0 ANTIBODY TRANSPORT MODEL 
As discussed in Chapter 2.0, SAF-based antibody removal must be reasonably fast as 
well as selective if the platform is to be clinically valuable. In this chapter, we describe the 
development of a mathematical antibody transport model that accounts for antibody diffusion, 
convection, and reversible binding within the SAF fibers. The model is used to predict the 
magnitude of the SAF-based antibody removal rate, and to identify the removal rate-controlling 
antibody transport mechanisms, for clinically relevant SAF geometries, blood flow rates, 
antibody diffusivities, and antibody-binding rates. In Chapter 5.0, we describe in vitro antibody 
removal experiments performed to test key predictions of the mathematical model. Since the in 
vitro experiments involve SAF-based removal of antibodies from aqueous buffer (instead of 
blood), in this chapter we address antibody removal from aqueous buffer as well as antibody 
removal from blood. 
4.1 Model Geometry 
The SAF is modeled as a bundle of N identical cylindrical fibers of length L (cm) and 
inner radius a (cm) (Figure 4-1). Antibody solution (blood or aqueous buffer) enters the blood 
compartment of the SAF at free antibody concentration ci (g/ml) and flow rate Q (ml/min), and 
is distributed evenly among the fibers so that the flow rate through each fiber lumen is Q/N. The 
shell compartment of the SAF (the space outside the fibers) is filled with isotonic buffer and 
closed. Within each fiber lumen antibodies undergo axial convection and radial diffusion, and at 
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 the fiber wall the antibodies bind reversibly to the immobilized antigens (Figure 4-2). Antibody 
solution exits each fiber at “mixing cup” free antibody concentration co (g/ml), and the SAF-
based antibody removal rate is equal to the antibody solution flow rate Q multiplied by the 
difference between ci and co. 
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Figure 4-1 Schematic depicting blood flow through the blood compartment of a SAF. The 
shell compartment is filled with isotonic buffer and closed. The relative dimensions of the 
SAF fibers and the SAF housing are not to scale. 
4.2 Transport Formulation 
The quasi-steady mass conservation equation is used to describe the transport of free 
antibodies in the fiber lumen (122): 
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where c(r, z) (g/ml) is the concentration of free antibodies in the fiber lumen, vz(r) (cm/s) is the 
axial component of the antibody solution velocity, and D (cm2/s) is the diffusion coefficient of 
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 the antibodies in the antibody solution. Boundary conditions at the fiber wall, centerline, and 
inlet are required to solve equation (4-1) for c(r, z). An expression for the antibody solution 
velocity profile vz(r) is also needed. As discussed further below, the boundary condition at the 
fiber wall involves the bound antibody concentration cb (g/cm2), and thus is time-dependent 
since cb increases with time. However, the quasi-steady form of the mass conservation equation 
is appropriate since the time scale for a substantive change in cb is long compared to the 
residence time. 
co
Q/N
z
r
c(r,z): free Ab concentration
cb(z,t): bound Ab concentration
cs(z,t): free binding site concentration
Blood Flow
L
a
ci
Q/N
Immobilized Antigen (Ag)
Pathogenic Antibody (Ab)
Membrane Wall
 
Figure 4-2 Schematic depicting antibody removal in the lumen of a single SAF 
fiber, with model parameters described in the preceding text. The relative 
dimensions of the fiber lumen and the antibodies and antigens are not to scale. 
At the inner fiber wall, the radial antibody flux is equal to the antibody-binding rate per 
unit of fiber surface area:  
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 where kf (ml/g*s) is the intrinsic association rate constant for the antibody/antigen system, kr  
(s-1) is the intrinsic dissociation rate constant for the antibody/antigen system, cb (g/cm2) is the 
bound antibody concentration, and csi (g/cm2) is the antibody-binding capacity of the SAF. The 
antibody concentration profile in each fiber is symmetric with respect to radial position, and the 
antibody solution enters each fiber with a flat concentration profile:  
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Finally, cb(z, t) is determined by integrating the radial antibody flux at the fiber wall over time: 
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4.3 Flow of Blood or Aqueous Buffer in SAF Fibers 
The physical properties (density and viscosity) of blood and dilute aqueous buffer (water) 
are listed in Table 4-1. 
Table 4-1 Physical Properties of Blood and Water (123-125) 
Fluid Density (g/ml) Viscosity at 22 	C, cP Viscosity 37 	C, cP 
Blood (40% 
Hematocrit) 1.058 4.8 (at high shear rates) 3.5 (at high shear rates) 
Water 1.0 1.0 0.7 
The SAFs used clinically will contain between 6000 and 32,000 fibers of 25 cm length 
and 0.01 cm inner radius (Table 2-5). For water flow through a small SAF (6000 fibers), the 
Reynolds number in each SAF fiber lumen is below 14 when the water flow rate is below 500 
ml/min (Figure 4-3). For water flow through a large SAF (32,000 fibers), the Reynolds number 
 66
 is below 3 when the water flow rate is below 500 ml/min. Under the same conditions as those 
described above, the Reynolds number for blood flow is less than that for water flow since blood 
is more viscous (and only slightly more dense) than water (Figure 4-3). Hence, the flow of blood 
or aqueous buffer is laminar within each fiber lumen. Blood is a non-Newtonian fluid, but 
behaves as a Newtonian fluid for when the shear rate is greater than 100 s-1 (126). For flow 
through a small SAF (6000 fibers), the shear rate at the inner wall of each fiber exceeds 100 s-1 
when the flow rate exceeds 30 ml/min, and for flow through a large SAF (32,000 fibers) the 
shear rate at the inner wall of each fiber exceeds 100 s-1 when the flow rate exceeds 150 ml/min 
(Figure 4-4). Hence blood can be considered a Newtonian fluid as it flows through the SAF 
provided that the flow rate is sufficiently high. For laminar flow of a Newtonian fluid in a 
circular tube, the entrance length, relative to the total length of the tube, can be estimated 
(127,128): 
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where Le is the entrance length (cm) and Re is the Reynolds number. For the small SAF (6000 
fibers), the entrance length is less than 0.1% of the SAF fiber length (for Re less than 14). For the 
large SAF (32,000 fibers), the entrance length is less than 0.06% of the SAF fiber length (for Re 
less than 3).  
Hence the flow of blood or dilute aqueous buffer in each fiber lumen is laminar and fully 
developed, and the fluid velocity profile is the parabolic velocity profile characteristic of 
laminar, fully developed flow of a Newtonian fluid in a circular tube (122):  
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where vavg (cm/s) is the average fluid velocity in the fiber.  
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 During SAF-based antibody removal the net ultrafiltration rate (flow rate of buffer or 
plasma water from the blood compartment to the shell compartment) is zero since the shell 
compartment is filled with isotonic buffer and closed. However, buffer or plasma water re-
circulates between the blood and shell compartments because the hydrostatic pressure in the 
lumen of each fiber decreases along the length of the fiber, while the hydrostatic pressure in the 
shell compartment is constant (and equal to the average of the inlet and outlet lumenal pressures 
(129)). This re-circulation (Starling re-circulation) has a negligible effect on the fluid flow in the 
fiber lumens if the ratio of the lumenal flow resistance (Rl) to the trans-membrane flow resistance 
(Rt) is less than one (129): 
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where  is the blood or buffer viscosity (cP) and Lp (ml/mmHg*hr) is the hydraulic permeability 
of a single SAF fiber. For Hemophan® hollow fiber dialysis membranes (used in the in vitro 
experiments reported in Chapters 3.0 and 5.0), the hydraulic permeability of a single fiber of 25 
cm length and 0.01 cm inner radius is 9*10-4 ml/hr*mmHg (100). Thus for blood flow at 37 ºC, 
Rl/Rt is equal to 0.04. (In vivo SAF-based antibody removal will occur at 37 ºC to avoid 
delivering cool blood to the patient.) For water flow at 22 ºC, Rl/Rt is equal to 0.01. (The in vitro 
antibody removal experiments described in Chapter 5.0 were performed at 22 ºC for simplicity.) 
In both cases, the Starling re-circulation has a negligible effect on the fluid flow in the fiber 
lumens. 
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Figure 4-3 Reynolds numbers in the fiber lumens of 2 SAFs 
containing the smallest (SAF 1) and largest (SAF 2) number of 
fibers expected for clinical SAFs.  
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Figure 4-4 Wall shear rates in the fibers comprising 2 SAFs containing the 
smallest (SAF 1) and largest (SAF 2) number of fibers expected for 
clinical SAFs.  
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 4.4  Dimensional Analysis 
We used the dimensionless variables and groups listed in Table 4-2 to simplify the 
solution and interpretation of the transport model. We normalized the radial position by the inner 
radius of each SAF fiber, and we normalized the axial position by the length of each fiber: r* = 
r/a and z* = z/L. We normalized the free antibody concentration by the inlet free antibody 
concentration, and we normalized the bound antibody concentration by the SAF antibody-
binding capacity: c* = c/ci, and cb* = cb/csi. The dimensionless form of the mass conservation 
equation involves the Graetz number (Gz): 
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The Graetz number (Gz = a2vavg/LD) represents the ratio of the characteristic radial diffusion 
time to the residence time (122). As Gz approaches infinity, ∂c*/∂z* approaches zero since the 
time required for the antibodies to diffuse to the immobilized antigens is much longer than the 
time the antibodies spend in the SAF. Using a small SAF (6000 fibers), the Graetz number for 
IgG antibodies is between 7 and 143 when the antibody solution flow rate is between 25 and 500 
ml/min, and the Graetz number for IgM antibodies is between 19 and 397 for the same antibody 
solution flow rate range (Figure 4-5). Using a large SAF (32,000 fibers), the Graetz number for 
IgG antibodies is between 1 and 26 when the antibody solution flow rate is between 25 and 500 
ml/min, and the Graetz number for IgM antibodies is between 3 and 74 for the same antibody 
solution flow rate range. (For these calculations to apply to antibody removal from blood at 37 
ºC, we must assume that the antibody diffusivity in flowing blood is equal to the antibody 
diffusivity in flowing water, and we must neglect the effect of temperature on antibody 
 70
 diffusivity. These calculations are only strictly correct for antibody removal from aqueous buffer 
at 22 ºC.) 
Table 4-2 Dimensionless Variables and Groups 
Variable Description 
ic
cc *  Free Antibody Concentration 
i
s
b
b c
cc *  Bound Antibody Concentration 
a
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The dimensionless form of the wall boundary condition involves the Damköhler number 
(Da): 
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where Kd (g/ml) is the equilibrium dissociation constant for the antibody/antigen system. The 
Damköhler number (Da = kfcsia/D) represents the ratio of the characteristic antibody-binding 
rate to the characteristic radial antibody diffusion rate. As Da approaches infinity, antibodies that 
reach the fiber wall bind “instantaneously” and antibody transport in the fiber lumen is controlled 
by the rate of antibody diffusion (diffusion-limited). Conversely, as Da approaches zero, 
antibodies that bind to antigens are replaced “instantaneously” by diffusion of antibodies farther 
from the fiber wall, and antibody transport in the fiber lumen is controlled by the rate of 
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 antibody-binding (reaction-limited). For kf between 10-5 and 10-2 ml/g*s (104 to 106 L/mol*s), 
the Damköhler number for SAF-based IgG removal is between 0.1 and 300, and the Damköhler 
number for SAF-based IgM removal is between 1 and 800 (Figure 4-6). (Again, for these 
calculations to apply to antibody removal from blood at 37 ºC, we must assume that the antibody 
diffusivity in flowing blood is equal to the antibody diffusivity in flowing water, and we must 
neglect the effect of temperature on antibody diffusivity. These calculations are only strictly 
correct for antibody removal from aqueous buffer at 22 ºC.) To make these estimates, we chose 1 
g/cm2 as an order of magnitude estimate of the antibody-binding capacity of the SAF, since the 
approximate surface concentration of a monolayer of IgG molecules is 0.6 g/cm2 (101,102). We 
chose the antibody/antigen association rate constant range based on the reported rate constants 
for antibody/antigen systems with either the antibodies or the antigens immobilized (106,107). 
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Figure 4-5 Graetz numbers for IgG and IgM antibodies for flow 
through 2 SAFs containing the smallest (SAF 1) and largest (SAF 
2) number of fibers expected for clinical SAFs. 
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Figure 4-6 Damköhler numbers for SAF-based removal of IgG and 
IgM antibodies, over the clinically relevant range of 
antibody/antigen association rate constants. 
The dimensionless forms of the centerline and inlet boundary conditions are 
straightforward: 
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The equation for the dimensionless bound antibody concentration involves the Graetz 
number and the ratio of the mass of free antibodies in one fiber volume (Vfci) to the mass of 
antibody-binding sites on the wall of one fiber (SAfcsi); 
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where Vf (ml) and SAf (cm2) are the lumenal volume and surface area of a single SAF fiber, 
respectively. Thus cb* rises slowly with time if the mass of antibody-binding sites on the fiber is 
large compared to the mass of antibodies in the antibody solution. Also, cb* rises slowly with 
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 time if Gz is large, since ∂c*/∂z* is small for large Gz and most of the antibodies that enter the 
SAF leave without binding to antigen. 
4.5 Numerical Solution for Small cb* 
We used FlexPDE (PDE Solutions, Inc., Antioch, CA), a finite element-based partial 
differential equation solver, to obtain numerical solutions for c*(r*, z*) for any combination of 
Da and Gz and for cb* near zero (i.e. far from saturation of the SAF). We then calculated the 
“mixing cup” antibody concentration at the SAF outlet, co (g/ml) (122): 
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Finally we determined the antibody removal rate R (g/min) (R = Q(ci - co)) and the antibody 
clearance K (ml/min) (K = R/ci = Q(1 - co/ci)). The clearance represents the volume of antibody 
solution completely depleted of antibodies per unit time, and is a more useful indicator of SAF 
performance than the antibody removal rate since the clearance depends only on the percent 
reduction in antibody concentration accomplished by the SAF, and is independent of the actual 
antibody concentration levels in the blood (130). For cb* near zero (i.e. far from saturation of the 
SAF), the mass conservation equation and the boundary conditions are linear with respect to the 
free antibody concentration, and hence co is linearly proportional to ci and the clearance is 
independent of ci. 
4.6 Analytical Solutions for Large and Small Da and Small cb* 
We obtained analytical solutions for c*(r*, z*), co/ci, and K for large and small 
Damköhler numbers and for cb* near zero (i.e. far from saturation of the SAF). As Da 
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 approaches infinity, the left side of equation (4-2a) approaches zero and the wall boundary 
condition can be simplified: 
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Thus for large Da, antibodies that reach the fiber wall bind “instantaneously” and the free 
antibody concentration at the fiber wall is equal to the equilibrium free concentration, calculated 
using the Langmuir adsorption isotherm equation (107). For large Da and for cb* equal to zero, 
c*(1, z*) is equal to zero. With this simplified boundary condition, we calculated c*(r*, z*) and 
co/ci using the infinite series Graetz solution for radial diffusion in a circular tube with constant 
wall concentration (131). The solution in this limiting case (Da→∞) was designated the 
diffusion-limited solution, since the antibody removal rate was determined by the diffusion rate 
and was independent of the binding rate. The expressions for c*(r*, z*) and co/ci, and the needed 
eigenvalues, eigenfunctions, coefficients, and derivatives, are presented in Skelland (131). 
As Da approaches zero, ∂c*/∂r* approaches zero throughout the fiber lumen (equation 
(4-2a)). In this case we treated the antibody-antigen binding as a homogeneous reaction:  
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The solution for co/ci was straightforward: 
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The solution in this limiting case (Da→0) was designated the reaction-limited solution, since the 
antibody removal rate was determined by the antibody-binding rate and was independent of the 
diffusion rate (note that Da/Gz is independent of D). 
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 4.7 Model Predictions 
4.7.1 Dimensionless Free Antibody Concentration Profiles 
Figure 4-7 shows the dimensionless free antibody concentration profiles at the SAF fiber 
outlet for Damköhler numbers between 0.1 and 100, and for reaction-limited and diffusion-
limited antibody transport. In each simulation the Graetz number is equal to 12.5 and cb* is equal 
to zero. The numerically generated concentration profiles for finite Da approach the analytically 
generated diffusion-limited and reaction-limited profiles for large and small Damköhler 
numbers, respectively. In each profile, except the reaction-limited profile, the dimensionless 
antibody concentration is highest at the fiber centerline and lowest at the fiber wall due to 
binding of free antibodies at the wall. The diffusion-limited profile is the sharpest, with the 
dimensionless outlet concentration decreasing from about 0.6 at the fiber centerline to zero at the 
fiber wall. The profiles flatten with decreasing Damköhler number, and for reaction-limited 
antibody transport the dimensionless outlet concentration is about 0.95 at all radial positions (Da 
= 0.1). 
4.7.2 Dependence of the Dimensionless Clearance on the Damköhler Number 
Figure 4-8 shows the dependence of the dimensionless clearance (K/Q) on the 
Damköhler number, for Graetz numbers of 12.5, 25.1, and 50.2. In each simulation cb* is equal 
to zero. Recall that the clearance represents the volume of antibody solution completely depleted 
of antibodies per unit time. Hence the dimensionless clearance represents the fraction of the 
antibody solution flow completely depleted of antibodies, and equals one if the antibody 
concentration at the SAF outlet equals zero. Figure 4-8 reveals the approximate boundaries of 
three antibody transport regimes, defined by the magnitude of the Damköhler number: reaction-
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 limited (Da ≤ 0.1), intermediate (0.1 < Da < 10), and diffusion-limited (Da ≥ 10). The 
dimensionless clearance is very low (< 0.05) in the reaction-limited regime. In the intermediate 
regime, the dimensionless clearance is higher (up to 0.6 at Gz equal to 12.5 and Da equal to 10) 
and increases substantially with increasing Damköhler number. The dimensionless clearance is 
highest in the diffusion-limited regime and no longer increases with increasing Damköhler 
number. As expected, at all Damköhler numbers the dimensionless clearance decreases with 
increasing Graetz number.  
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Figure 4-7 Dimensionless antibody concentration profiles within a SAF 
fiber at the fiber outlet, for Damköhler numbers between 0.1 and 100 and 
for diffusion-limited and reaction-limited antibody transport. The Graetz 
number is 12.5 and the dimensionless concentration of bound antibodies 
is near zero. 
4.7.3 Dependence of Dimensionless Clearance on the Graetz Number 
Figure 4-9 shows the dimensionless clearance, relative to the dimensionless clearance at 
Graetz number equal to 10, as a function of the Graetz number. In each simulation cb* is equal to 
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 zero. The dimensionless clearance is shown in normalized form to allow visual comparison of 
the simulations at different Damköhler numbers. As also shown in Figure 4-8, the dimensionless 
clearance decreases with increasing Graetz number at all Damköhler numbers; however, the rate 
at which the dimensionless clearance decreases with increasing Graetz number is slowest for 
diffusion-limited transport. For Da equal to one, increasing the Graetz number from 10 to 50 
causes a 74% reduction in K/Q, while for diffusion-limited transport, the same increase in Gz 
causes only a 56% reduction in K/Q. 
 
0
0.2
0.4
0.6
0.8
0.01 0.1 1 10 100 1000
Da
K/
Q
Gz = 12.5
Gz = 50.2
Gz = 25.1
Diffusion-limited
cb* ~ 0
 
Figure 4-8 Dependence of the dimensionless clearance (K/Q) on the 
Damköhler number (Da), for Graetz numbers (Gz) equal to 12.5, 25.1, and 
50.2. Dashed lines indicate the dimensionless clearance for diffusion-
limited antibody transport at each Graetz number. The dimensionless 
concentration of bound antibodies is near zero. 
4.7.4 Dependence of Clearance on the Antibody Solution Flow Rate 
The increase in clearance with increasing antibody solution flow rate is greatest for 
diffusion-limited antibody transport (Figure 4-10), since the decrease in dimensionless clearance 
 78
 with increasing flow rate (and Graetz number) is least for diffusion-limited transport (as 
explained above). For a SAF with the same geometry as the prototypes used in our in vitro 
studies (Chapter 5.0), increasing the flow rate from 50 to 100 ml/min increases the clearance 
from 15.0 to 17.0 ml/min (12.5%) when Da is equal to one, and from 33.6 to 47.6 ml/min (34%) 
when the transport is diffusion-limited. Therefore diffusion-limited antibody transport is doubly 
advantageous, producing the highest clearance at a given flow rate and the greatest increase in 
clearance when the flow rate is raised. 
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Figure 4-9 Dependence of the dimensionless clearance (K/Q), relative 
to the dimensionless clearance at Graetz number (Gz) equal to 10, on 
Graetz number, for Damköhler numbers of 1 and 10 and for diffusion-
limited antibody transport. The dimensionless concentration of bound 
antibodies is near zero. 
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Figure 4-10 Dependence of clearance (K) on antibody solution flow rate 
(Q), for Damköhler numbers (Da) of 1 and 10 and for diffusion-limited 
antibody transport. The SAF geometry is identical to the geometry of the 
SAF prototypes used for the in vitro experiments reported in Chapter 5.0. 
The dimensionless concentration of bound antibodies is near zero. 
4.8 Discussion 
Our transport model revealed three antibody transport regimes, defined by the magnitude 
of the Damköhler number Da: reaction-limited (Da ≤ 0.1), intermediate (0.1 < Da < 10), and 
diffusion-limited (Da ≥ 10). For a given SAF geometry, blood flow rate, and antibody 
diffusivity, the highest antibody clearance, and hence the highest antibody removal rate, is 
predicted for diffusion-limited antibody transport. In each regime, the antibody clearance 
increases with increasing blood flow rate. However, the greatest percent increase in clearance 
accomplished by raising the blood flow rate occurs when the antibody transport is diffusion-
limited. At a given blood flow rate, the clearance for diffusion-limited antibody transport can be 
increased even further by using a SAF with more fibers (i.e. decreasing the Graetz number at the 
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 same blood flow rate). Diffusion-limited antibody transport in the SAF fibers may be achievable 
for medium to high affinity IgG antibodies (kf >5*10-4 ml/g*s) and IgM antibodies (kf >2*10-4 
ml/g*s), if the SAF fibers have enough antibody-binding sites to obtain near monolayer 
coverage of bound antibodies at saturation (Figure 4-6).   
The above insights suggest a unified approach to the design of SAF modules for clinical 
applications: 
1. Optimize the form of the antigen (i.e. natural or synthetic, with or without a spacer 
molecule), and the method for immobilizing the antigen on the inner fiber walls, to obtain the 
highest possible antibody-binding capacity and hence to maximize the chances of achieving 
diffusion-limited antibody transport. 
2. Use the highest possible blood flow rate, within the limits of biocompatibility and patient 
stability. 
3. Use a SAF with the largest possible number of fibers possible, within the limits of 
biocompatibility and cost. 
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 5.0 IN VITRO MEASUREMENT OF THE SAF-BASED ANTIBODY REMOVAL 
RATE IN A MODEL ANTIBODY/ANTIGEN SYSTEM 
As discussed in Chapter 4.0, antibody transport in the SAF fibers may be primarily 
controlled by the rate of antibody-antigen binding (reaction-limited transport) or by the rate of 
radial antibody diffusion (diffusion-limited transport), or both rates may be important 
(intermediate transport). For a given SAF geometry, blood flow rate, and antibody diffusivity, 
the antibody removal rate is highest when the antibody transport is diffusion-limited. 
Additionally, when diffusion-limited antibody transport is achieved, the antibody removal rate is 
independent of the antibody-binding rate and hence is the same for any antibody/antigen system 
and for any patient within one antibody/antigen system. In this chapter, we describe a series of in 
vitro antibody removal experiments performed to determine whether diffusion-limited antibody 
transport is achieved in SAF prototypes containing immobilized protein-based antigens. The in 
vitro antibody removal experiments were performed using a model antibody/antigen system 
instead of a human disease-related system, to eliminate the need for a human source of 
antibodies and to allow all of the experiments to be performed using antibodies and antigens 
from single lots. We chose bovine serum albumin (BSA) as our model antigen, since BSA is a 
large molecular weight protein (132) like the ligands used in immunoadsorption columns (such 
as protein A and anti-human immunoglobulin), is inexpensive and non-toxic, and can be 
immobilized on cellulose-based SAF fibers using conventional protein immobilization methods. 
We used polyclonal anti-BSA antibodies as our model antibodies, and compared both the 
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 magnitudes and the parameter-dependencies of the measured anti-BSA removal rates to the 
predictions of our mathematical model.  
5.1 Methods 
5.1.1 SAF Fabrication 
Gambro (Lakewood, CO) 500 HG hemodialyzers were used as SAF modules. The 
modules contained approximately 6656 Hemophan® fibers of 0.02 cm nominal inner diameter 
and 25.6 cm length, providing a blood-contacting surface area of 1.1 m2 (100). Bovine albumin 
(BSA) (Sigma Chemical Co., St. Louis, MO) or human albumin (HSA) (Alpine Biologics Inc., 
Orangeburg, NY) was immobilized on the lumenal surfaces of the fibers using a modified 
version of the cyanogen bromide activation method developed by Axen et al (119). Unless 
otherwise noted, chemicals were obtained from Sigma Chemical Company (St. Louis, MO). 
During the following fiber activation steps, the blood and shell compartments of the SAF module 
were connected in series using tygon tubing. Both compartments of the module were first rinsed 
copiously with de-ionized water. To swell the fibers, 3.5 L of 0.2 N NaOH was circulated 
through the module for four hours, on ice, at 136 ml/min. The module was flushed with 3.5 L of 
0.1 M sodium bicarbonate buffer/0.5 M NaCl, pH 8.3 (henceforth called bicarbonate buffer), at 
225 ml/min and at 4 ˚C. An activating solution of 25 g CNBr in 250 ml of 0.2 N NaOH was 
circulated through both compartments at 136 ml/min, on ice, for 1.5 hours. The activating 
solution pH was kept above 11.0 by the addition of cold 10 N NaOH. The module was flushed 
with 3.5 L of de-ionized water and 3.5 L of bicarbonate buffer, at 225 ml/min and at 4 ˚C. Excess 
fluid was removed from the module using filtered compressed air.  
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 The shell compartment was then filled with bicarbonate buffer and closed. One hundred 
ml of 20-mg/ml antigen solution (BSA, HSA, or a mixture of BSA and HSA, dissolved in 
bicarbonate buffer) was circulated through the blood compartment at 77 ml/min, at room 
temperature, overnight (at least 12 hours). Both compartments were drained, and the mechanical 
integrity of the fibers and the seal separating the blood and shell compartments was verified by 
checking for antigen in the buffer drained from the shell compartment. The blood and shell 
compartments were again connected in series and the SAF was washed four times, by circulating 
500 ml of bicarbonate buffer through the SAF at 136 ml/min for one hour (each wash). Un-
reacted active sites on the fibers were capped by circulating 250 ml of 1 M ethanolamine, pH 8.3, 
through the SAF at 77 ml/min for two hours. The SAF was flushed with 3.5 L of bicarbonate 
buffer (at 225 ml/min), 2 L of 0.1 M glycine, pH 2.5 (at 77 ml/min), and 7 L of phosphate-
buffered saline (PBS) (137 mM NaCl/2.7 mM KCl/10 mM Na2HPO4/1.76 mM KH2PO4), pH 7.4 
(at 225 ml/min). Finally, 3.5 L of PBS was circulated through the SAF at 136 ml/min overnight 
(at least 12 hours). Excess fluid was removed from the SAF using filtered compressed air, and 
the SAF was stored at 4 ˚C until use.  
5.1.2 Antibody Solution Preparation 
Affinity purified, polyclonal sheep anti-BSA antibodies of IgG isotype were obtained 
from Bethyl Laboratories, Inc. (Montgomery, TX). The antibodies were supplied as a 1-mg/ml 
stock solution in PBS/0.1% NaN3, and stored at 4 ˚C until use. For each antibody removal 
experiment, an appropriate volume of stock solution was added to PBS, pH 7.4, to obtain the 
desired concentration and volume of anti-BSA solution. All antibodies used were from the same 
lot. 
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 5.1.3 Antibody Concentration Measurement 
An in-house enzyme-linked immunosorbent assay (ELISA) (133) was used to measure 
the anti-BSA concentrations of samples collected during each experiment. Anti-BSA standards 
with concentrations between 2 and 40 ng/ml were prepared for construction of a reference curve. 
Each of the following solutions was added to the plate at 100 l/well. Ten g/ml BSA in 0.1 M 
sodium carbonate buffer, pH 9.6, was added to each well of a high-binding Costar 96-well EIA 
plate (Fisher Scientific, Pittsburgh, PA) and the plate was incubated at 37 ˚C for 1 hour. The 
plate was washed 5 times with 10 mM tris/100 mM NaCl/0.05% Tween 20, pH 7.4. The anti-
BSA samples to be assayed (diluted appropriately in PBS/0.05% Tween 20, pH 7.4) and the anti-
BSA standards were added to the plate in duplicate, and the plate was incubated for 1 hour at 37 
˚C and washed 5 times. Horseradish peroxidase-conjugated anti-sheep IgG antibodies (Bethyl 
Laboratories, Inc., Montgomery, TX), diluted to 1 g/ml in PBS/0.05% Tween 20, pH 7.4, were 
added to the plate, and the plate was incubated for 1 hour at room temperature and washed 6 
times. TMB peroxidase substrate (KPL, Gaithersburg, MD) was added to the plate, and the plate 
was incubated for 15 minutes at 37 ˚C. Finally, 1 M phosphoric acid was added to the plate, and 
the optical density of each well was measured at 450 nm using a microplate reader (Molecular 
Devices, Sunnyvale, CA). The concentration of each test sample was calculated by comparison 
to the reference curve. 
5.1.4 Adsorption Isotherm Experiments 
The adsorption isotherm for binding of anti-BSA antibodies to immobilized BSA was 
measured by incubating samples of Hemophan® fibers, with BSA immobilized on the outer 
surfaces of the fibers, in anti-BSA solutions of varying concentrations. Bovine serum albumin 
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 (BSA) was immobilized on the outer surfaces of the fibers comprising a Gambro 500 HG 
hemodialyzer using a modified version of the cyanogen bromide activation method developed by 
Axen et al (119). The immobilization was performed as described above (5.1.1), except that the 
20-mg/ml antigen solution was circulated through the shell compartment (instead of the blood 
compartment) after the fiber activation steps. The SAF was disassembled and the fibers were 
carefully extracted from the housing. Anti-BSA solutions at concentrations of 0.5, 1, 5, 10, 15, 
and 20 g/ml were prepared using PBS/0.05% Tween 20, pH 7.4, as the diluent. For each anti-
BSA solution, 3 ml was placed in a 12 x 75 mm disposable glass test tube containing 200 
Hemophan®/BSA fibers of 2 cm length, and 3 ml of was placed in a second test tube containing 
200 un-modified Hemophan® fibers of 2 cm length. The tubes were capped and rocked gently 
for 6 hours at room temperature, and the anti-BSA concentration in the supernatant of each tube 
was measured using the ELISA described above (5.1.3). The bound antibody concentration was 
calculated by multiplying the difference between the initial and final anti-BSA concentrations by 
the antibody solution volume (3 ml) divided by the fiber surface area (27 cm2). The data was fit 
to the Langmuir adsorption isotherm equation (equation (2-1)) using a non-linear regression tool 
in Matlab (The Mathworks, Inc., Natick, MA), and the antibody-binding capacity (csi) and the 
equilibrium dissociation constant (Kd) were determined. 
5.1.5 In Vitro Perfusion System 
In vitro antibody removal experiments were performed using the simple perfusion system 
shown in Figure 5-1. The system consisted of a glass antibody solution reservoir, a Masterflex 
peristaltic pump (Cole-Parmer Instrument Company, Vernon Hills, IL), a glass bead flow meter 
(Cole-Parmer Instrument Company), a SAF, and a sampling port at the SAF outlet. The 
components were connected using tygon tubing. The shell compartment of the SAF was filled 
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 with PBS and closed, and the antibody solution was pumped solely through the blood 
compartment. The entire perfusion system, except the reservoir, was de-aired and primed with 
PBS prior to the antibody removal experiment. At the start of the experiment the reservoir was 
filled with anti-BSA solution and the solution was pumped through the blood compartment of the 
SAF at the prescribed flow rate. 
Pump
SAF
Flow Meter
Anti-BSA 
Solution at ci Sampling 
Port
 
Figure 5-1 Perfusion system for in vitro antibody removal 
experiments. 
5.1.6 In Vitro Antibody Removal Experiments 
During each antibody removal experiment, approximately one L of antibody solution was 
pumped through a freshly fabricated SAF in single pass mode at constant flow rate. (A control 
SAF with immobilized HSA was the only SAF used in multiple anti-BSA removal experiments.) 
Eight 1 ml outlet samples and two inlet samples were collected and assayed for anti-BSA 
concentration. The clearance was calculated using the mean concentrations of both inlet samples 
and the second through eighth outlet samples. Negligible rise of the outlet anti-BSA 
concentration with time verified that cb* remained near zero during each experiment. 
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 The first series of experiments was performed to determine the dependence of antibody 
clearance on inlet anti-BSA concentration. Anti-BSA removal experiments were performed at 
inlet concentrations of 0.5, 1, and 2 g/ml, at a flow rate of 47 ml/min, using SAFs with 
immobilized BSA. The chosen anti-BSA inlet concentrations were within the range of specific 
antibody concentrations reported in the literature (56,104). To check for non-specific anti-BSA 
removal, an experiment was performed using a SAF with immobilized HSA (which does not 
bind the anti-BSA used, data not shown), at an inlet concentration of one g/ml and a flow rate 
of 47 ml/min.  
The second series of experiments was performed to determine the dependence of 
antibody clearance on antibody solution flow rate. An anti-BSA removal experiment was 
performed at a flow rate of 110 ml/min and an inlet concentration of 2 g/ml, using a SAF with 
immobilized BSA, and the measured clearance was compared to the previously measured 
clearance at 47 ml/min. Again the SAF with immobilized HSA was used to check for non-
specific anti-BSA removal at 110 ml/min.  
The third series of experiments was performed to determine the dependence of antibody 
clearance on antibody-binding capacity. To fabricate a SAF with decreased anti-BSA-binding 
capacity, we used an antigen solution containing 10 mg/ml BSA and 10 mg/ml HSA. Using this 
SAF, we measured the clearance at an inlet concentration of one g/ml and a flow rate of 47 
ml/min, and compared the measured clearance to that measured for the SAFs with immobilized 
BSA only. 
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 5.2 Results 
5.2.1 Anti-BSA/Immobilized BSA Adsorption Isotherm 
The measured anti-BSA binding capacity of the Hemophan®/BSA fibers was 0.92 
g/cm2, and the equilibrium dissociation constant was 3.1 g/ml (Figure 5-2). The measured 
anti-BSA binding capacity is reasonable since the approximate surface concentration of a 
monolayer of IgG molecules is 0.6 g/cm2 (101,102). The measured equilibrium dissociation 
constant is also reasonable, based on the reported dissociation constants for antibody/antigen 
systems with either the antibodies or the antigens immobilized (Table 2-5) (1,106,107).  
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Figure 5-2 Anti-BSA/BSA adsorption isotherm for Hemophan® fibers 
with BSA immobilized on the outer surfaces of the fibers. Closed 
symbols: fibers with immobilized BSA. Open symbols: un-modified 
Hemophan® fibers.    
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 5.2.2 Outlet Anti-BSA Concentration as a Function of Throughput 
During each anti-BSA removal experiment, the anti-BSA concentration at the SAF outlet 
increased sharply with the first 200 ml of throughput (volume of antibody solution perfused 
through the SAF) as the priming solution was flushed from the perfusion system (Figure 5-3). 
The outlet concentration remained relatively constant for the remainder of the experiment (up to 
800 ml throughput), indicating that the increase in bound anti-BSA concentration during the 
experiment was negligible compared to the anti-BSA-binding capacity of the SAF (i.e. cb* was 
near zero throughout the experiment). 
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Figure 5-3 Anti-BSA outlet concentration relative to inlet concentration 
(co/ci) during a typical anti-BSA removal experiment. Throughput is the 
volume of anti-BSA solution perfused through the SAF. Closed 
symbols: SAF with immobilized BSA. Open symbols: control SAF with 
immobilized HSA. Each experiment was performed at an anti-BSA 
solution flow rate of 47 ml/min and an anti-BSA inlet concentration of 
one g/ml. 
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 5.2.3 Dependence of Anti-BSA Clearance on ci 
As expected for cb* approximately equal to zero, the anti-BSA clearance was 
independent of anti-BSA inlet concentration for inlet concentrations between 0.5 and 2 g/ml 
(Figure 5-4). At an anti-BSA solution flow rate of 47 ml/min, the average of the clearances 
measured at inlet concentrations of 0.5, 1, and 2 g/ml was 26.3 ml/min, and the non-specific 
clearance by the control SAF (at an inlet concentration of one g/ml) was 2.8 ml/min. The 
measured clearance using the SAFs with immobilized BSA, minus the non-specific clearance, 
was approximately 73% of the predicted diffusion-limited clearance and was within 2% of the 
clearance predicted for Damköhler number equal to 3.  
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Figure 5-4 Dependence of anti-BSA clearance (K) on anti-BSA inlet 
concentration (ci). Each experiment was performed at an anti-BSA 
solution flow rate of 47 ml/min. Dashed lines indicate the predicted 
clearances for Damköhler number (Da) equal to 1, 3, and 5, and for 
diffusion-limited antibody transport.   
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 5.2.4 Dependence of Anti-BSA Clearance on Anti-BSA Solution Flow Rate 
Anti-BSA clearance increased to 36.2 ml/min when the anti-BSA solution flow rate was 
raised to 110 ml/min (Figure 5-5). The non-specific clearance by the control SAF was 6.8 
ml/min at a flow rate of 110 ml/min.  The measured clearance using the SAF with immobilized 
BSA, minus the non-specific clearance, was approximately 60% of the predicted diffusion-
limited clearance and was within 5% of the clearance predicted for Damköhler number equal to 
3.  
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Figure 5-5 Dependence of anti-BSA clearance (K) on anti-BSA 
solution flow rate (Q). Simulated dependences of clearance on flow 
rate, for Damköhler number (Da) equal to 1, 3, and 5, and for diffusion-
limited antibody transport, are also shown. 
5.2.5 Dependence of Anti-BSA Clearance on Antibody-Binding Capacity 
At an anti-BSA solution flow rate of 47 ml/min, the anti-BSA clearance decreased to 16.2 
ml/min when the anti-BSA-binding capacity decreased by approximately 50% (Figure 5-6). The 
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 measured anti-BSA clearance using the SAF with immobilized HSA and BSA, minus the non-
specific clearance by the control SAF, was within 10% of the clearance predicted for Damköhler 
number equal to 1. 
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Figure 5-6 Dependence of anti-BSA clearance (K) on antigen 
composition. Each experiment was performed at an anti-BSA 
solution flow rate of 47 ml/min. Dashed lines indicate the predicted 
clearances for Damköhler number (Da) equal to 1, 3, and 5, and for 
diffusion-limited antibody transport. 
5.3 Discussion 
Transport of anti-BSA antibodies in SAF prototypes with immobilized BSA occurred in 
the intermediate regime, at a Damköhler number approximately equal to 3, and hence both the 
anti-BSA-binding rate and the radial anti-BSA diffusion rate were important determinants of the 
anti-BSA removal rate. At anti-BSA solution flow rates of 47 and 110 ml/min, we found close 
agreement between the measured anti-BSA clearances and the model-predicted clearances for 
Damköhler number equal to 3. Additionally, the anti-BSA clearance was highly dependent on 
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 the anti-BSA-binding capacity of the SAF, as expected for antibody transport in the intermediate 
regime. Based on our initial estimates of the expected Damköhler number for SAF-based IgG 
removal, we expected the anti-BSA transport in the SAF prototypes to be diffusion-limited. 
Several factors may have contributed to the low Damköhler number achieved in our model 
system. In our SAF prototypes, BSA was immobilized on the fibers via accessible primary 
amines on the BSA. Since BSA contains 59 primary amine-containing lysine residues (132), of 
which about 30-35 are on the surface and available as immobilization points (134), the 
population of immobilized BSA was heterogeneous and a fraction of the BSA may have been 
unable to bind anti-BSA. Additionally, immobilization of the BSA may have reduced the 
intrinsic anti-BSA/BSA association rate constant and produced a low affinity antibody-antigen 
system. Finally, the anti-BSA population used may have had a low intrinsic affinity for BSA. 
Several antigens used for immunoadsorption are available in synthetic form, and can be 
immobilized via spacer molecules to ensure that most of the epitopes are accessible to the 
antibodies (89,91). SAFs containing these antigens may have antibody-binding capacities high 
enough to produce diffusion-limited transport of medium and high affinity antibodies. During 
development of SAFs for clinical use, equilibrium antibody-binding experiments must be 
performed to measure the antibody-binding capacity of the SAF fibers and ensure that the 
immobilization method is optimal. 
Our antibody transport model can be used to determine the SAF-based antibody removal 
rate if the SAF geometry, blood flow rate, antibody diffusivity, and antibody-binding rate are 
known. The model can also be used to help assess how close a given system is to achieving 
diffusion-limited antibody transport. For example, if the anti-BSA/BSA system were a system of 
clinical relevance, we would continue the SAF prototype development with the goal of tripling 
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 the anti-BSA-binding capacity of the SAF fibers and increasing the Damköhler number to 9. 
Further development to increase the Damköhler number past 9 or 10 would be unwarranted, 
since the model predicts little enhancement in clearance obtained by raising the Damköhler 
number above 10.  
Our transport model does not account for the inherent heterogeneity of polyclonal 
antibodies. As antibody populations do not display a Gaussian distribution of affinities in vivo 
(23), appropriate mathematical representation of antibody heterogeneity is difficult and requires 
extensive knowledge of the antibody/antigen system being studied. Use of an “average” value for 
kf may over-predict the clearance since the clearance depends non-linearly on kf (i.e. the slow 
clearance of low affinity antibodies is not balanced by the fast clearance of high affinity 
antibodies).  
SAF antibody clearance from flowing whole blood may be higher than clearance from 
plasma or buffer due to enhancement of the antibody diffusivity in flowing blood compared to 
the diffusivity in flowing cell-free solutions. At a shear rate of 500 s-1, the IgG diffusivity in 
flowing human blood may be about 6 times its magnitude in stationary blood or about three 
times its magnitude in water (135). Transport of buffer-dissolved anti-BSA antibodies in our 
SAF prototypes with immobilized BSA occurred at a Damköhler number approximately equal to 
3, and we estimate that kfcsi was approximately equal to 5.9*10-5 cm/s in that system (D equal to 
3.9*10-7 cm2/s). At a blood flow rate of 110 cm3/min, using a SAF with the same geometry as the 
prototypes used in our in vitro studies and the same magnitude for kfcsi, the predicted antibody 
clearance increases from 31 to 42 ml/min when the antibody diffusivity increases from 3.9*10-7 
to 11.7*10-7 cm2/s. Under the same conditions, the predicted clearance for diffusion-limited 
antibody transport increases from 50 to 71 ml/min. The higher percent increase in clearance for 
 95
 diffusion-limited antibody transport, compared to the increase for intermediate antibody 
transport, reflects the greater dependence of clearance on the antibody diffusion rate in the 
diffusion-limited regime. 
A single compartment pharmacokinetic model is typically used to describe the drop in the 
pathogenic antibody concentration in the patient’s blood volume during an antibody removal 
session (136):  
 
bl
bl Kc
dt
dcV   (5-1)
where V is the blood volume (cm3) and cbl is the patient’s blood antibody concentration (g/cm3). 
If the clearance is constant throughout the antibody removal session, the antibody concentration 
decays exponentially with time, with a time constant equal to V/K. For a clearance of 29.4 
ml/min, at a blood flow rate of 110 ml/min (as achieved with our SAFs with immobilized BSA), 
the time constant for treatment of a 5 L blood volume is 170 minutes or 2.8 hours. For diffusion-
limited transport at the same blood flow rate, the time constant is 101 minutes or 1.7 hours. In 
practice, the clearance will decrease as the concentration of bound antibodies becomes non-
negligible compared to the capacity of the SAF (i.e. as cb* becomes non-negligible). To limit this 
reduction, the SAF must contain an abundance of antibody-binding sites compared to the mass of 
pathogenic antibodies in the patient’s blood at the beginning of the antibody removal session. 
Alternatively, two SAFs can be simultaneously employed during each removal session, with one 
SAF removing antibodies while the other is undergoing antibody elution and regeneration. This 
strategy is currently employed for IgG removal using the Excorim protein A columns (3). 
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 6.0 CONCLUSIONS 
1. Removal of anti-A and anti-B antibodies from whole human blood using SAFs containing 
immobilized protein-based A and B antigens is feasible, and may be preferable to the non-
selective or semi-selective anti-A and anti-B removal methods that are currently available. 
2. Antibody transport in the SAF fibers may be primarily controlled by the rate of antibody-
antigen binding (reaction-limited transport) or by the rate of radial antibody diffusion 
(diffusion-limited transport), or both rates may be important (intermediate transport). For a 
given SAF geometry, blood flow rate, and antibody diffusivity, the antibody removal rate is 
highest when the antibody transport is diffusion-limited. Additionally, when diffusion-
limited antibody transport is achieved, the antibody removal rate is independent of the 
antibody-binding rate and hence is the same for any antibody/antigen system and for any 
patient within one antibody/antigen system.  
3. Transport of anti-BSA antibodies in SAF prototypes with immobilized BSA occurred in the 
intermediate regime, at a Damköhler number approximately equal to 3, and hence both the 
anti-BSA-binding rate and the radial anti-BSA diffusion rate were important determinants of 
the anti-BSA removal rate. Based on our initial estimates of the expected Damköhler number 
for SAF-based IgG removal, we expected the anti-BSA transport in the SAF prototypes to be 
diffusion-limited. Several factors may have contributed to the low Damköhler number 
achieved in our model system, including randomly-oriented immobilization of the BSA.  
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 4. Initial SAF development work should focus on achieving diffusion-limited antibody transport 
by increasing the SAF antibody-binding capacity. If diffusion-limited transport is achieved, 
modifications to the SAF geometry and blood flow through the SAF can further increase the 
antibody removal rate. 
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 APPENDIX A 
FlexPDE Script for Numerical Solution of the Antibody Transport Model 
{***************************************************************************** 
 This program simulates steady state antibody removal by a hollow fiber-based SAF. 
 Blood is perfused through the SAF at constant inlet concentration and constant  
 flow rate. The dimensionless outlet antibody concentration, dimensionless antibody 
 clearance, and dimensional clearance are determined as functions of the Damkohler  
 number and the Graetz number. 
*****************************************************************************} 
title "Antibody Removal by SAF" 
coordinates 
 xcylinder(z,r) 
{ r = dimensionless radial coordinate, z = dimensionless axial coordinate } 
variables 
C  { dimensionless concentration of free antibodies } 
definitions 
Q = 47  { blood flow rate, ml/min } 
a = 0.01  { SAF fiber radius, cm } 
L = 25.6 { SAF fiber length, cm } 
N = 6656 { number of SAF fibers } 
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 D = 3.9*10^(-7) 
{ diffusion coefficient of antibodies in blood, cm2/s} 
kfcs = 1.17*10^(-4) 
{ forward binding velocity, cm/s } 
vbar = Q/(60*N*pi*a^2) 
{ average velocity of blood in the SAF, cm/s } 
Gz = pi*vbar*a**2/(L*D) 
{ Graetz number } 
Da = kfcs*a/D  
{ Damkohler number } 
v = 2*(1-r^2) { dimensionless velocity profile } 
Cout = surf_integral(v*c,"outlet")/surf_integral(v,"outlet") 
{ mean dimensionless concentration at SAF outlet } 
KdivQ = 1 – Cout 
{ dimensionless antibody clearance } 
K = KdivQ*Q  
{ dimensional antibody clearance, ml/min } 
equations 
Gz/pi*v*dz(C) = 1/r*dr(r*dr(C)) 
boundaries 
Region  { define cylinder of radius = 1 centered at 0,0} 
start (1,0) line to (1,1) 
 
natural(C) = Da*C 
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 line to (0,1) 
value(C) = 1 line to (0,0) 
natural(C) = 0  
line to finish  
feature start "outlet" (1,0) 
line to (1,1) 
plots   {show final solution} 
elevation(C) from (1,0) to (1,1) 
elevation(C) from (0,1) to (1,1) 
report Gz report Da report Cout report KdivQ report K  
end 34287 
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